CONFIDENTIAL  Page  1 of 115   
 
 
 
 
A Multi -center, Randomized, Double -blind,  Placebo -controlled  Trial, Followed 
by [CONTACT_294307] -arm Treatment of PRO  140 in Combination With  Optimized  
Background Therapy  in Treatment- Experienced  HIV -1 Subjects.  
   
 
Protocol Number:  PRO  140_CD 02 
Version:  9.0 
Date:  08-Jan-2018  
 
   
Sponsor:  CytoDyn, Inc. 
[ADDRESS_1035133] 
Vancouver, Washington [ZIP_CODE]  
(360)  980-8524- Work  
(360)  980-8549- Fax 
www.cytodyn.com  
     
Confidentiality  Statement 
This document is a confidential communication of  CytoDyn, Inc. It is provided for the conduct 
of a clinical research study. The information contained in this document is confidential and, 
except to the extent necessary to obtain informed consent or IEC/IRB approval, cannot be disclosed unless required by [CONTACT_26463]. Persons to whom any portion of the 
contents of this document is disclosed must be informed that the information is confidential and may not be further disclosed by [CONTACT_476]. 
 
 
 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  2 of 115  
  
PROTOCOL APPROVAL PAGE 
 
Protocol Number:  PRO  140_CD 02 
Version:  9.0 
Date:  08-Jan-[ADDRESS_1035134] read the protocol and the appendices and agree  that it contains all relevant  information 
required to meet FDA, GCP and all applicable regulatory guidelines and statutes.  

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  3 of 115  
  
INVESTIGATOR’S  SIGNATURE [CONTACT_118258]:  PRO  140_CD 02 
Version:  9.0 
Date:  08-Jan-2018  
 
 
 
 
 
INVESTIGATOR’S  SIGNATURE 
I have read the protocol  specified above and agree to participate in and comply with the  
procedures, as outlined herein for the conduct of this clinical trial. I also agree to comply with the 
applicable US Food and Drug Administration (FDA) regulations and Investigational Review Board 
(IRB) requirements for testing on human subjects. I agree to ensure that the requirements for 
obtaining informed consent are met. 
 
 
 
 
 
Principal  Investigator’s  Signature  [CONTACT_756457]  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035135] 
Vancouver, Washington [ZIP_CODE]  
(360)  980-8524- Work  
(360)  980-8549- Fax 
www.cytodyn.com  
 
   
CONTRACT  RESEARCH  ORGANIZATION  INFORMATION  
 
 
 
 
 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035136]  ........................................................ 25 
1.4 Summary  of Prior Pre-Clinical And Clinical  Studies  ......................................................... 25 
1.4.1 Pre-Clinical Studies with PRO 140 ................................................................... 25 
1.4.2 Clinical Studies  with PRO 140 ......................................................................... 26 
[IP_ADDRESS] PRO  140 1101 Study ........................................................................................ 26 
[IP_ADDRESS] PRO  140 1102 Study ........................................................................................ 26 
[IP_ADDRESS] PRO  140 1103 Study ........................................................................................ 26 
[IP_ADDRESS] PRO  140 1302 Study ........................................................................................ 27 
[IP_ADDRESS] P
RO 140 2301 Study ........................................................................................ 30 
[IP_ADDRESS] PRO  140 2101 Study ........................................................................................ 30 
[IP_ADDRESS] PRO  140 _CD01 Study ..................................................................................... 33 
[IP_ADDRESS] PRO 140 _CD01-Extension Study  ................................................................... 35 
[IP_ADDRESS] PRO  140 _CD03 Study  ..................................................................................... 35 
1.5 Rationale for Dose  Selection  .............................................................................................. 38 
1.6 Risks  / Benefits  Assessment  ............................................................................................... 39 
1.6.1 Risks/Discomfort to Subjects and Precautions  to Minimize  Risk....................................... 39 
[IP_ADDRESS] Risks associated with continuation of Failing Antiretroviral Treatment 
Regimen  ............................................................................................................ 39 
[IP_ADDRESS] Allergic  Reaction  .............................................................................................. 39 
[IP_ADDRESS] Immune  Response  ............................................................................................. 40 
[IP_ADDRESS] Pregnancy  ......................................................................................................... 40 
[IP_ADDRESS] Venipuncture  ..................................................................................................... 40 
[IP_ADDRESS] Risks  to the Study Personnel and the Environment  .......................................... 40 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  15 of 115  
 [IP_ADDRESS] Unknown Risks  .................................................................................................. 40 
[IP_ADDRESS] Theoretical  risk for increased  severity  of West  Nile virus infection  ................. 40 
1.6.2 Intended Benefit  for Subjects  ............................................................................................... 41 
2 STUDY OBJECTIVES  .......................................................................................................... 42 
3 STUDY DESIGN .................................................................................................................... 43 
3.1 Study Center(s) .................................................................................................................... 43 
3.2 Study Population  ................................................................................................................... 44 
3.3 Eligibility  Criteria  ................................................................................................................ 44 
3.3.1 Inclusion Criteria  ............................................................................................... 44 
3.3.2 Exclusion Criteria  .............................................................................................. 45 
4 STUDY SCHEDULE ............................................................................................................. 49 
4.1 Screening  Phase  ................................................................................................................... 56 
4.1.1 Screening  Visits  ................................................................................................. 56 
4.2 Treatment  Phase  ................................................................................................................... 57 
4.2.1 Treatment  Visit (T1) - Part 1 of Treatment  Phase ............................................. 60 
4.2.2 Treatment  Visit -2 (T2) to Treatment  Visit-25 (T25)  - Part 2 of Treatment  Phase62  
4.2.3 End of Treatment  (EOT)  Visit  ........................................................................... 63 
4.2.4 T
reatment  Failure  (TF) Visit  ............................................................................. [ADDRESS_1035137] Receipt  and Accountability  ............................................................ 75 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035138] Disposition  ...................................................................................... 75 
7 DESCRIPTION OF PROTOCOL ASSESSMENTS  AND PROCEDURES  ..................... 76 
7.1 Informed  Consent  ................................................................................................................ 76 
7.2 Assessment  of Eligibility  ..................................................................................................... 76 
7.3 Demographic Information  .................................................................................................... 76 
7.4 Medical  History  ................................................................................................................... 76 
7.5 HIV History  ......................................................................................................................... 77 
7.6 Prior / Concomitant Medications and Non-Study Treatments  ............................................. 78 
7.6.1 Excluded Medications and Therapi[INVESTIGATOR_014]  ................................................................ 79 
7.6.2 Allowable  Medications and Therapi[INVESTIGATOR_014] ............................................................... 79 
7.7 Physical  Examination  .......................................................................................................... 79 
7.8 Electrocardiogram  ................................................................................................................ 80 
7.9 Neurological Assessment  ..................................................................................................... 80 
7.10 Vital Signs (inc. height and weight) .................................................................................... [ADDRESS_1035139] .......................................................................................... 82 
7.11.7 Plasma HIV-1 RNA level  and TruCount T Assay  ............................................. 82 
7.11.8 HIV-1 Trofile®  Assay  ....................................................................................... 82 
7.11.9 HIV-1 Drug  Resistance Assay  ............................................................................ 82 
7.11.10 HIV-1 PhenoSense® Entry  assay  ...................................................................... 83 
7.11.11 Serum  Concentration of ART  drugs  .................................................................. 83 
7.11.12 Blood sample collection  for Exploratory/Confirmatory analysis ...................... [ADDRESS_1035140] Administration  ................................................................................. 84 
7.14 Injection  Site Reaction  assessment  ...................................................................................... 84 
7.15 Pain Assessment  using Visual  Analog Scale (VAS)  ............................................................ 85 
8 STATISTICAL  CONSIDERATIONS  .................................................................................. 86 
8.1 Tr
eatment  Groups  ................................................................................................................ 86 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  17 of 115  
 8.2 Description  of Study Endpoints  ........................................................................................... 86 
8.2.1 Primary  Efficacy  Endpoints  ............................................................................... 86 
8.2.2 Secondary Efficacy  Endpoints  ........................................................................... 86 
8.2.3 Safety  Assessments  ............................................................................................ 87 
8.3 Sample  Size Determination  and Rationale .......................................................................... 87 
8.4 Randomization and Blinding  ............................................................................................... 87 
8.5 Interim  Analysis  ................................................................................................................... 88 
8.6 General  Statistical  Considerations  ....................................................................................... 88 
8.6.1 Analysis Populations  .......................................................................................... 88 
[IP_ADDRESS] Intent- to-Treat  Population .................................................................................. 88 
[IP_ADDRESS] Per Protocol Population  ..................................................................................... 89 
[IP_ADDRESS] Safety  Population  ............................................................................................... 89 
8.6.2 Statistical Methods  ............................................................................................. 89 
8.6.3 Prognostic  Factors/Covariates ............................................................................ [ADDRESS_1035141] Disposition  ............................................................................................ 89 
8.7.2 Demographic and Baseline Characteristics........................................................ 90 
8.7.3 Prior and Concomitant Medications  .................................................................... 90 
8.7.4 E
fficacy  Analysis  ............................................................................................... 90 
[IP_ADDRESS] Primary  Analysis  ................................................................................................ 90 
[IP_ADDRESS] Supportive Analysis  ........................................................................................... 91 
8.7.5 Safety  Analysis  .................................................................................................. 91 
[IP_ADDRESS] Adverse Events  ................................................................................................... 91 
[IP_ADDRESS] Tolerability  Assessment  ..................................................................................... 92 
[IP_ADDRESS] Clinical Laboratory Data ................................................................................... 92 
[IP_ADDRESS] Physical  Examination  ........................................................................................ 92 
[IP_ADDRESS] Vital Signs  .......................................................................................................... 92 
[IP_ADDRESS] ECG Exami nation  .............................................................................................. 92 
[IP_ADDRESS] Neurological Assessment  ................................................................................... 92 
9 ADVERSE EVENTS  (DEFINITIONS  AND REPORTING)  .............................................. [ADDRESS_1035142] of Study Treatment  ................................................................................ 93 
9.1.3 DAIDS  AE Grade  (Severity) Assessment  .......................................................... 93 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  18 of 115  
 9.1.4 Causality  Assessment  ....................................................................................... 94 
9.1.5 Treatment  Given as a Result  of the Event  ........................................................ 95 
9.1.6 Outcome Assessment  ........................................................................................ 95 
9.1.7 Expected  / Anticipated  Adverse Events ............................................................ 95 
9.1.8 SC Injection -related  Events  .............................................................................. 96 
9.2 Serious Adverse Events  (SAE)  ........................................................................................... [ADDRESS_1035143] ACCESS  TO SOURCE  DATA/DOCUMENTATION ....................................... 99 
11 QUALITY CONTROL  AND QUALITY ASSURANCE ................................................. 100 
11.1 Monitoring Requirements  ................................................................................................. 100 
11.2 Acceptability  of Case Report Forms  (CRFs)  .................................................................... 100 
11.3 Modification  of Protocol  ................................................................................................... 101 
11.4 Reporting Protocol Deviations  .......................................................................................... 101 
12 DATA MONITORING  COMMITTEE (DMC)  ............................................................... [ADDRESS_1035144]/Independent Ethics  Committee  (IRB/IEC)  ........................... 103 
13.2 Inv
estigator’s  Responsibilities  .......................................................................................... [ADDRESS_1035145] KEEPI[INVESTIGATOR_1645]  .............................................................. 105 
14.1 Recording and Collection of Data .................................................................................... 105 
14.2 Clinical Data  Management  ............................................................................................... 105 
14.3 Archiving  .......................................................................................................................... 106 
15 PUBLICATION  PLAN ....................................................................................................... 107 
16 REFERENCES  .................................................................................................................... 109 
17 APPENDIX  .......................................................................................................................... 111 
17.1 Appendix I: AIDS -Defining  Conditions  ........................................................................... 111 
17.2 Appendix II: Division of AIDS Table for Grading the Severity of Adult and Pediatric  
Adverse Events (DAIDS  AE Grading Table)  .............................................................................. 113 
17.3 Appendix III: Adverse Events of Special  Interest: Injection  Site Reactions ................... 114 
17.4 Appendix V: Neurological Assessment  ............................................................................ 115 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035146] OF TABLES  
 
Table  1-1: Clinical Studies  with PRO 140 .............................................................................. 36 
Table  4-1: Schedule of Assessments  – Screening  and Treatment  Phase  ................................. 52 
Table  4-2: Schedule of Assessments  –Follow- Up (FU)  Phase  ................................................ 55 
Table 4 -3 Part 1: One week double-blind, placebo-controlled period [IP (PRO 140 or  
Placebo)  + existing  ART]  ...................................................................................... 58 
Table  4-4 Part 2: 24- week  treatment maintenance period [PRO  140 + OBT]  ....................... 58 
Table  6-1: Investigational Product - PRO 140/Placebo at T1 visit ......................................... 70 
Table  6-2: Investigational Product - PRO 140 at T2 - T25 visit ............................................. 71 
Table  9-1: DAIDS  AE Grading Table  v2 General  Guidelines  ................................................ 94 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035147] OF FIGURES  
Figure 1- 1: PRO 140 1302 Study: Mean  of the maximum (nadir) log 10 reductions in HIV RNA  
. .............................................................................................................................. 27 
Figure 1- 2: PRO 140 1302 Study: Mean  log 10 reductions in HIV RNA over time .................. 28 
Figure 1- 3: PRO 140 1302 Study: PRO 140 serum concentrations following a single  
intravenous injection in HIV - infected individuals ............................................... 29 
Figure 1- 4: PRO 140 2301 Study: Mean change from baseline in HIV- 1 RNA ( Log 10 
copi[INVESTIGATOR_014]/mL)  over Time  (ITT  Subjects)  ................................................................... 30 
Figure 1- 5: PRO 140 2101 Study: Mean  of the maximum (nadir) log 10 reductions in HIV RNA  
. .............................................................................................................................. 31 
Figure 1- 6: PRO 140 2101 Study: Mean change from baseline in HIV- 1 RNA (Log 10 
copi[INVESTIGATOR_014]/mL)  over Time  (ITT  Subjects)  ................................................................... 32 
Figure 1- 7: Change in CD4+  cell counts in subjects treated  with subcutaneous PRO  140. ..... 33 
Figure 1- 8: Emax  analysis of antiviral data generated  with IV  and SC PRO  140. ................... 38 
Figure 3- 1: Study Flow  Diagram  .............................................................................................. 48 
Figure 4- 1: Study Schematic  .................................................................................................... 49 
Fi
gure 6- 1: Investigational Product - Vial Label  ...................................................................... 71 
Figure 6- 2: Investigational Product - Syringe Label  ................................................................ 72 
Figure 6- 3: Investigational Product - Kit Label  ........................................................................ 73 
Figure 7- 1: Visual  Analog Scale ............................................................................................... 85 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035148] Aspartate Transaminase 
ATC  Anatomic Therapeutic Classification  
AUC  Area Under  Curve  
°C Celsius  
CBC Complete  Blood Count  
CCR5  C-C chemokine  receptor  type [ADDRESS_1035149]  
et al et aliae;  Latin  for "and others"  
EOT  End of Treatment  
°F Fahrenheit  
FDA U.S. Food and Drug  Administration  
FDP Fixed  Dose Procedure  
FU Follow -Up 
GCP  Good Clinical Practice  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035150] 
HIV Human  Immunodeficiency  Virus  
IA Interim Analysis  
IB Investigator’s  Brochure  
ICF Informed Consent  Form  
ICH International  Conference on Harmonization  
i.e. id est; Latin  for “that is” 
IEC Independent  Ethics  Committee  
IND Investigational  New Drug  
INR International Normalized  Ratio  
IP Investigational  Product  
IRB Institutional Review Board  
ISR Injection  Site Reactions  
ITT Intent -to-treat 
IV Intravenous 
LAR  Legally  Acceptable Representative  
LDH Lactate dehydrogenase 
LPN Licensed  Practical  Nurse 
LVN Licensed  Vocational  Nurse  
mAb  Monoclonal  Antibody  
MD Doctor  of Medicine  
MedDRA  Medical  Dictionary  for Regulatory  Activities 
mg Milligram  
mL Milliliter  
mm Millimeter  
MOCA Montreal  Cognitive  Assessment  
MW Molecular  Weight  
NCS  Not Clinically Significant  
NP Nurse Practitioner  
NTF Non-Treatment  Failure  
OBT  Optimized  Background Therapy  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035151] Upper  limit of normal  
[LOCATION_003] United  States  of America  
VAS  Visual  Analogue  Scale  
WBC White  Blood Cells  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035152] and reporting of this trial shall be conducted in compliance with the 
protocol, International Conference on Harmonization/Good Clinical Practice (ICH/GCP), and all appropriate regulatory requirements. Investigator(s) participating in this study will have documented training in GCP. Independent monitoring of the trial will be accomplished utilizing 
 as the Contract Research Organization (CRO).  
 
1.[ADDRESS_1035153] two decades in the development of effective and well tolerated combination antiretroviral regimens, nearly 25% of patients  
receiving Highly Active Antiretroviral Therapy (HAART) are not virologically suppressed due  
to various reasons. Recent data su ggest that most virologic failure on first- line regimens occurs 
because of either pre -existing (transmitted) drug resistance or suboptimal adherence.  Patient - 
and regimen -related factors play a crucial role in determining whether an antiretroviral regimen  
is successful or result in virologic failure [Office of AIDS Research Advisory Council, 2014]. 
In general, drug resistance can be considered a core issue in patients with limited treatment 
options. However, there are other known factors apart from drug res istance (such as incomplete 
adherence, medication intolerance, pharmacokinetic issues, etc.) which also contribute to  
limiting treatment options in constructing a new regimen for patients who experience treatment failure. New agents and drug classes (e.g., integrase inhibitors, fusion inhibitors and CCR5 
antagonists) are necessary to keep up with ongoing viral mutations in an attempt to prevent viral replication and transmission [Tang MW, 2012][Gulick RM, 2008][Moyle G, 2008]. The availability of an effecti ve maintenance regimen would benefit a subset of HIV -1 infected 
persons who are challenged by [CONTACT_616510], medication adherence and/or chronic nucleoside toxicity. 
PRO [ADDRESS_1035154] any cross -resistance with 
drugs from other classes. Although PRO 140 would require subcutaneous (SC) administration,  
its favorable pharmacokinetics allows for weekly dosing. The purpose of this study is to exhibit 
antiviral activity of PRO 140 in combination with other antiretroviral agents for treatment of antiretroviral- experienced persons infected with CCR5 -tropic HIV -1 virus. 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035155] 
PRO 140 is a humanized IgG4,κ  monoclonal antibody (mAb) to the C -C chemokine receptor 
type 5 (CCR5), under development as a therapy for human immunodeficiency virus (HIV) 
infection.  
PRO 140 binds to the N terminus (Nt) and the extracellular loop 2 (ECL2) domain of the CCR5 cell surface receptor that HIV -1 uses to gain entry to a cell. PRO 140 binding to CCR5 blocks 
viral entry  by [CONTACT_756439]. PRO 14 0 has been administered intravenously or subcutaneously 
to 174 HIV -1 infected individuals in Phase I/II studies of safety, tolerability, pharmacokinetics 
and pharmacodynamics [Jacobson JM, 2010][Jacobson JM, 2010]. The drug has been well tolerated followin g administration of single doses of 0.5 to 5 mg/kg or up to three weekly doses 
of up to [ADDRESS_1035156] been  conducted to support the clinical  developmen t plan. 
Acute toxicity of PRO 140 was evaluated in New Zealand rabbits, following IV administration of 5 or 15 mg/kg. Chronic toxicity was evaluated in cynomolgus monkeys following biweekly administration of IV doses up to 10 mg/kg for six months and biweekly administration of various SC  doses up to  50 mg/kg for  24 weeks.  The drug was generally  well tolerated.  Biweekly 
administration of IV doses up to 10 mg/kg for six months resulted in minimum to mild  
lymphoid hyperplasia in assorted lymph nodes and spleen, which was considered an expected immune response to a foreign protein. Biweekly administration of SC doses up to 50 mg/kg for 24 weeks resulted in minimum injection -site reactions (minimal, multifocal, mononuclear cell 
infiltrates in the subcutis), which  were considered due to an inflammatory response to the 
injected antigen. Monkeys tolerated treatment with PRO [ADDRESS_1035157]  body weight, food consumption, hematology, clinical  chemistry  or coagulation  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  26 of 115  
 parameters.  
Both IV and SC administration resulted in elimination half- lives of approximately 200 hours, 
and overall exposure increased with increasing doses. Following SC administration of PRO 140 
in monkeys, the maximal concentration (C max) was achieved within 56 hours and bioavailability 
for PRO 140 after SC dosing was approximately 70%. 
1.4.2 Clinical Studies  with  PRO  140 
Current human experience with PRO 140 consists of seven completed clinical trials. These studies are summarized in Table  1-1.  In all clinical trials, the majority of adverse events (AEs) 
were mild or moderate. No dose -limiting toxicities or patterns of drug -related toxicities were 
observed. Antiviral activity was potent, rapid, prolonged, dose -dependent, and highly  
signific ant. 
[IP_ADDRESS] PRO  [ADDRESS_1035158] -in-human trial, PRO 140 1101, the drug was administered IV at 0.1, 0.5, 2.0, or 5.0 
mg/kg and was generally well tolerated, non- immunogenic, and without clinically relevant 
toxicity. Treatment Emergent Adverse Events (TEAEs) did not increase with rising PRO 140 dose levels. 75% of subjects reported TEAEs, most of which were deemed unrelated to study treatment.  
[IP_ADDRESS] PRO  140 1102 Study  
In PRO 140 1102 study, the majority  of AEs, other than injection- site reactions, were considered 
mild and possibly r elated to drug administration. The majority of injection -site reactions were 
considered mild, self -resolving, and definitely related to drug administration. PRO 140 derived 
from Chinese Hamster Ovary (CHO) cells and administered SC at 100 mg/mL was generally  
well tolerated  in healthy, normal  volunteers. Overall,  PRO  [ADDRESS_1035159]® 
2 appeared better tolerated than manual injection.  
[IP_ADDRESS] PRO  [ADDRESS_1035160]® [ADDRESS_1035161] perception of pain or discomfort related to site of drug administration. No anti -PRO 140 antibodies were detected in 
any subjects in this study. There was a tendency of higher exposure associated with SC administration of PRO 140 at 350 mg in the abdomen and the thigh. A higher number of AEs were associated with injections in the arm. Based on these observations, thigh and abdominal administration of PRO 140 were preferred over arm injection.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  28 of 115  
 Figure  1-2:  PRO  140 1302 Study:  Mean  log [ADDRESS_1035162] -generation Trofile assay. CCR5- only tropi[INVESTIGATOR_756424], with two exceptions: One of nine (11%) of placebo subjects had dual/mixed virus at baseline and all subsequent timepoints, reflecting a spontaneous and stable switch in co- receptor tropi[INVESTIGATOR_616482]. One of 30 (3%, 0.5 
mg/kg group) had a dual/mixed tropi[INVESTIGATOR_616483] 8 and CCR5- only results at all other 
timepoints, including the end of the day [Jacobson JM, 2008]. Clonal analysis of the dual/mixed virus revealed that it reflected outgrowth of pre -existing undetected virus rather than mutation of 
an CCR5 virus to a dual/mixed virus following treatment [Marozsan, 2008]. Therefore, no significant development of viral resistance to PRO 140 was observed despi[INVESTIGATOR_616484] (2- 3 weeks on average) viral suppression, followed by [CONTACT_616512]. 
Given that  resistance to other classes of HIV -1 drugs can develop within one week of 
monotherapy [Demeter LM, 2000] [Saag, 1993][Richman, 1994], the findings indicate that PRO 140 presents a high barrier to viral resistance in vivo. 
Figure 1-3 illustrates the mean serum concentrations of  PRO 140 after IV  injection. Serum levels 
increased  with increasing  dose. The mean  Area  Under Curve (AUC)  from time zero to infinity  

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  30 of 115  
 [IP_ADDRESS] PRO  [ADDRESS_1035163] bo-controlled, parallel group 
study in 30 male and female adult subjects infected with HIV -1. Subjects were randomized to  
one of three groups (N=10/group), each receiving one of three treatments: (i) a single IV dose of 
5 mg/kg by 30- minute  IV infusion; (ii) a single  IV dose of 10 mg/kg by 30- minute  IV infusion;  
(iii) a single placebo dose  by 30- minute IV  infusion. The  objective of the study was to assess and 
characterize the PK and PD of PRO 140 administered by [CONTACT_16228], assess efficacy at a new dosage level, and safety and tolerability of single doses of PRO 140. 
All PRO 140 -treated subjects had more than 10 -fold reduction in viral loads (mean max log
10 
reductions were 1.83 for treatment groups and 0.32 for placebo) ( Figure 1-4). Both the 5 mg/kg 
and 10 mg/kg doses have shown favorable tolerability and no dose -limiting toxicity has been 
observed. High levels of receptor occupancy (>85% reduction in the number of cells detected) were observed for 29 days after treatment with both 5 and 10 mg/kg doses. 
 
 
Figure 1 -4: PRO  140 2301 Study:  Mean  change  from  baseline  in HIV -1 RNA (Log 10 
copi[INVESTIGATOR_014]/mL) over Time (ITT Subjects)  
 
 
 
 
[IP_ADDRESS] PRO  140 2101 Study  
A subcutaneous (SC) form of PRO 140 was tested in HIV -infected subjects. The trial was a 
randomized,   double-blind,  placebo -controlled   study  in  subjects   (n=44)   with   early -stage,  

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  31 of 115  
 asymptomatic HIV infection, only CCR5 HIV -1 detectable, and no antiretroviral therapy for 12 
weeks [Thompson, 2009]. Placebo (n=10) and three PRO 140 doses were examined: 162mg 
weekly for three weeks (n=11), 324mg weekly for three weeks (n=11), and 324mg biweekly (every  other week) for  two doses (n=12). Subjects were  followed for  44 days after  the final dose. 
The study enrolled 40 males and 4 females. The median age, weight, CD4
+ cell count and HIV -1 
RNA at baseline were 42.3 years, 79.1 kg, 410 cells/μL and 20,000 copi[INVESTIGATOR_014]/mL, respectively. Baseline characteristics were similar for the different treatment groups.  
Potent, dose -dependent and highly statistically  significant antiviral activity  was observed ( Figure  
1-5 and Figure 1-6). The 324mg weekly dose resulted in a mean 1.65 log
10 reduction in viral 
load, and highly significant reductions were observed for the other dose groups as well ( Figure  
1-5). There was no viral rebound between 324mg doses, and the antiviral effects persisted for  
one week after the final dose ( Figure 1 -6). The trial established the first antiviral proof of 
concept for a long- acting, self -administrable drug for HIV -1 infection [Thompson, 2009]. 
 
Figure  1-5:   PRO  140 2101 Study:  Mean  of the maximum (nadir)  log 10 reductions  in HIV 
RNA 
 
 
placebo  
 
162mg Days  1,8,15  
 
324mg Days  1, 15 
 
2 
 
 
1.5 
 
 
1 
 
 
0.5 
 
 
0 
324mg  Days  1,8,15  
 
1.65 
 
1.37 
0.58 
0.23 Mean  Maximum  Log10 Reduction  in HIV RNA  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  33 of 115  
 Figure  1-7:  Change  in CD4+  cell counts  in subjects  treated  with  subcutaneous  PRO  140. 
Subjects (n=10 to 12 per group) were randomized to received placebo weekly (Days 1, 8, 15), 
162mg PRO  140 weekly  (Days  1, 8, 15), 324mg PRO 140 biweekly (Days 1, 15, with placebo  on 
Day 8), or  324mg PRO 140 weekly (Days 1, 8, 15). CD4+ cell counts were measured over time, 
and the median change from baseline was determined for each treatment group. 
 
125 
100 
75 
50 
25 
0 
-25 
-50  
 
1 8 15 22 29 36 43 50 57 64 125 
100 
75 
50 
25 
0 
-25 
-50  
 
1 8 15 22 29 36 43 50 57 64 
 
 
 
125 
100 
75 
50 
25 
0 
-25 
-50  
 
1 8 15 22 29 36 43 50 57 64 
Study Day  
125 
100 
75 
50 
25 
0 
-25 
-50  
 
1 8 15 22 29 36 43 50 57 64 
Study Day 
 
  
 
[IP_ADDRESS] PRO  140 _CD01  Study  
PRO 140_CD01 study (open-label, 43 subjects, multi-center) evaluated the efficacy, safety, and 
tolerability  of PRO 140 monotherapy  (350 mg subcutaneous injection weekly for up to 12 weeks) for 
the maintenance of viral suppression following substitution  of antiretroviral therapy in HIV-1 
324mg  Days 1,8,15 324mg  Days 1,15  
162mg  Days 1,8,15 
 Placebo  Median  Change  in CD4+  Cells  Median  Change  in CD4+  Cells  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  34 of 115  
 infected patients (with exclusive CCR5-tropic virus). Participants in this study were experienced 
HIV-infected individuals who were virologically suppressed on combination antiretroviral therapy. 
Consenting patients were shifted from combination antiretroviral regimen to PRO 140 monotherapy 
for 12 weeks. 
Forty (40) subjects (M/F: 37/3) with median age of 54.5 years (26-72) and median CD4 T -cell count 
of 604.5 cells/mm3 (365 -1240) were enrolled in the CD01 study. Overall, twenty-two out of 40 
(55%) enrolled subjects completed 12 weeks of PRO140 monotherapy without experiencing  
virologic failure. Virologic failure was defined as two consecutive HIV -1 RNA levels of ≥ 400 
copi[INVESTIGATOR_014]/mL separated by [CONTACT_2669] [ADDRESS_1035164] Dual/Mixed (D/M) tropi[INVESTIGATOR_8801] [1 at baseline and 2 at the time of virologic failure] and [ADDRESS_1035165] exclusive CCR5-tropic virus. Fifty-nine percent (59%) of CCR5-exclusive subjects 
compared to zero percent (0%) of D/M subjects experienced virologic success within 12 weeks of 
PRO140 monotherapy (p=0.0465). All virologic failure subjects who had available lab data in both 
studies achieved viral suppression to < 400 HIV -1 RNA copi[INVESTIGATOR_014]/mL, as well as viral suppression to 
‘Non Detectable’ or < 50 HIV-1 RNA copi[INVESTIGATOR_014]/mL after re-initiation of A RT. 
The by -subject analysis of PhenoSense® Entry Assay data for PRO140, maraviroc, and AMD3100 
shows no significant changes  in the post -treatment IC50 and IC90 values  were  noted when compared 
with baseline values in virologic failure and non-virologic failure groups of subjects. As the  
aggregate analysis shows, the subjects who experienced virologic failure had higher IC90 value for 
PR0140 at baseline compared to subjects without virologic failure. The mean IC90 for subjects who 
experienced virologic failure was higher (10.84 µg/mL) than the IC90 for subjects without virologic 
failure (6.70 µg/mL) in the CD01 study (p=0.0115). 
Anti-PRO140 antibodies were not identified in any post -treatment sample and data derived from the 
CD01 study further supports the favorable PRO140 PK profile data generated from both pre-clinical 
as well as prior Phase 1/2 clinical trials.  
Safety data were analyzed for all 40 enrolled subjects. One (1) of 40 subjects experienced an SAE that was deemed not related to the study drug by [CONTACT_079]. Twenty-eight (28) of 40 
subjects (70%) experienced one or more adverse events (AEs) after receiving at least one dose of 
PRO140. The most commonly occurring AEs were infections and infestation conditions which were 
reported by 14 of 40 (35%) subjects. The majority of the reported AEs (63/89; 70.7%) were deemed 
either unlikely or not related to study treatment by [CONTACT_737]. Similarly, the majority of the 
reported AEs (72/89; 80.8%) were deemed mild in nature. 
Additionally, a letter of amendment has been filed to increase the planned number of subjects from  
40 to 43 subjects to compensate for the 3 Dual/Mixed subjects (1 at baseline and 2 at the time of 
virologic failure) enrolled in the study. This clinical study is currently ongoing. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  35 of 115  
 [IP_ADDRESS] PRO  140 _CD01 -Extension Study  
PRO 140_CD01-Extension study (open-label, 28 subjects, multi -center) seeks to evaluate the 
efficacy, safety, and tolerability of PRO 140 monotherapy (350 mg subcutaneous injection weekly  
for up to 108 weeks) for the continued maintenance of viral suppression following substitution of 
antiretroviral therapy in HIV patients (with exclusive CCR5-tropic virus). Participants in this study 
were HIV -infected individuals who were virologically suppressed on combination antiretroviral 
therapy and completed the first  12 weeks of CD01 study without experiencing virologic failure. As 
with the CD01 study, virologic failure was defined as two consecutive HIV -1 RNA levels of ≥ 400 
copi[INVESTIGATOR_014]/mL separated by [CONTACT_2669] [ADDRESS_1035166] extension treatment. 
Fifteen (15) eligible subjects (M/F: 13/2) with median age of 55.3 years (26 -68) and median CD4 T- 
cell count of 586 cells/mm3 (365-1059) were enrolled in an extension study. Eleven (11) subjects are 
currently receiving weekly [ADDRESS_1035167] completed more than one  
year of treatment (56 - 67 wks). One subject with undetectable viral load did not continue beyond 47 
weeks due to relocation, and 3 subjects experienced virologic failure after a median time of 169 days 
(106- 193).  
PRO140 was generally well tolerated, and no drug-related SAEs were observed. The final clinical 
study report is expected to be available in 2017. 
This clinical study is currently ongoing. 
 
[IP_ADDRESS] PRO  140 _CD03  Study  
PRO 140_CD03 study (open- label, two -arm compara tor, 400 subjects, multi -center) seeks to 
evaluate the treatment strategy of using PRO 140 SC as long -acting single -agent maintenance 
therapy versus continuing combination ART for 48 weeks in virologically suppressed subjects 
with CCR5 -tropic HIV-1 infection. The study has been  submitted  to clinical  sites and  the start -up 
process is ongoing. 
Protocol  # PRO  140_CD  02 
Version  8.0 
Date:  08-Jan-[ADDRESS_1035168] (Emax) plot.  
Figure  1-8:
  Emax  analysis of antiviral data  generated  with  IV and SC PRO  140. 
 
The maximal viral load reduction was analyzed with regard to drug exposure for PRO 140. Figure 1 -8 above shows this relationship. Analysis shows that PR0 140 350mg weekly dose is 
expected to fall on the plateau of the Emax plot. 
The maximal change in HIV -1 viral load from baseline was  determined  at any  point 59 days after 
initiation of therapy. To allow approximate comparisons between the IV and SC doses, the 
overall AUC observed for repeat SC doses was conservatively estimated by [CONTACT_756440]0 -7d by [CONTACT_616515]. Viral load and AUC  data were fit to  
an Emax equation: E = Emax x AUC/(AUC + AUC50). The orange diamond indicates projected data for three weekly 350 mg doses based on the mean exposure observed in the PRO 140 1103 study.  
 
 
  
 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  39 of 115  
 It is important to note that when larger proteins (MW> 10,000) are administered SC, they 
initially traffic through the lymphatic system. Uptake into the bloodstream occurs after the 
proteins reach the thoracic duct [Nishikawa M, 2005]. 
In addition,  based on pharmacodynamic data from our prior SC and IV studies, maximum 
virologic suppression is expected to be achieved with trough concentrations that equal or exceed 
approximately 5 µg/mL. 
Finally, the mean nadir reduction in viral load achieved with 3 weekly 324 mg SC doses (1.65 
log 10) was similar  to the mean nadir reductions observed with single 5 or 10 mg/kg IV  doses (1.8 
log 10 in each case), and higher viral load reductions are expected in the present study based on  
the use of the 350 mg CHO formul ation. Overall, several lines of evidence indicate that 
maximum virologic suppression will be achieved with 350 mg weekly dosing in the present study.  
 
1.6 RISKS / BENEFITS  ASSESSMENT  
 
1.6.1 RISKS/DISCOMFORT TO SUBJECTS  AND PRECAUTIONS  TO MINIMIZE  RISK 
[IP_ADDRESS] Risks  associated  with  continuation  of Failing  Antiretroviral  Treatment  Regimen  
As per standard of care, patients who failing on their ART remain on failing regimen while waiting for the results of HIV -[ADDRESS_1035169]’s resistance test results and treatment history. This duration 
corresponds with the screening phase of the study. 
Once the results of resistance and tropi[INVESTIGATOR_616485], the study treatment (PRO 140 
350mg SC injectio n / placebo)  will be  added to the  failing  regimen for one week. After  one week 
all subjects will receive PRO 140 SC injection and Optimized Background Therapy (OBT). 
Addition of study treatment (PRO 140 350mg SC injection / placebo) to the failing regimen may 
not be effective in achieving a reduction in viral load for all subjects. Such cases could lead to  
an increased risk of developi[INVESTIGATOR_329483], opportunistic infections and cli nical progression 
of the disease.  
[IP_ADDRESS] Allergic Reaction  
PRO 140 belongs to the monoclonal antibody class of drugs. Monoclonal antibodies are 
sometimes associated with allergic reactions (fatigue, diarrhea, fever, vomiting, headache, nausea, pain at the site of  injection, low blood pressure, rash, itching, and chills) or flu -like 
reactions such as fever, chills, and aches. These events are usually  of short duration if they  occur 
at all. Severe allergic  reactions,  however, can be life-threatening. Although anaphylaxis  has not 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035170] the procedures required to manage  
anaphylactic shock. 
[IP_ADDRESS] Immune  Response  
Subjects who take PRO [ADDRESS_1035171] their ability to receive monoclonal antibodies, or to benefit from diagnosis or the rapy with a monoclonal antibody in the future. 
[IP_ADDRESS] Pregnancy  
Risks to unborn babies are unknown at this time; pregnant females will be excluded from this study. Females of  childbearing potential must have  a negative pregnancy test prior to enrollment. 
Both male and female patients and their partners of childbearing potential must agree to use appropriate birth control methods throughout the study duration (excluding women who are not of childbearing potential and men who have been sterilized). 
[IP_ADDRESS] Venipuncture  
Blood sampling is required as part of the study protocol. Blood sampling carries a minimal risk 
of minor discomfort and the possibility of minor bruising at the site of the needle puncture and, rarely, the possibility of infection at the needle puncture si te. 
[IP_ADDRESS] Risks  to the Study  Personnel  and the Environment  
The principal risk in the clinical setting is in the handling of needles that may be contaminated with HIV, or other human pathogens. Adherence to universal precautions for working with infectious agents  will reduce the risk of exposure to these individuals. All bio- hazardous waste 
will be disposed of as stipulated by [CONTACT_5737], state, and federal regulations and in accordance with study site Standard Operating Procedures (SOPs).  
[IP_ADDRESS] Unknown Risks  
As with all research there is the remote possibility of risks that are unknown or that cannot be 
foreseen based on current information.  
[IP_ADDRESS] Theoretical  risk for increased  severity  of West  Nile virus  infection  
Individuals who lack a functional CCR5 gene are at increased risk for severe infection by [CONTACT_520854] [Thompson, 2009] Because of this, treatment with CCR5 co- receptor antagonists  
poses a theoretical  risk for  increased severity  of West  Nile virus infection.  However, this  concern 
is mitigated  by [CONTACT_756441].  First, no increased  risk was observed  for individuals who possess  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035172] Nile virus [Thompson, 2009]. Second, use of CCR5 
co-receptor antagonists is unlikely  to completely  abrogate CCR5 function, and there has been no 
association reported to date between CCR5 co -receptor use and severe West Nile virus. 
Additionally, PRO [ADDRESS_1035173] supervised once weekl y SC treatment 
with PRO 140 in addition to an optimized and simplified ART regimen. Subjects participating in 
the present short term combination therapy study for 25 weeks will contribute to the  
development of a drug which has the potential to become a treatment option for them and others in the future. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  42 of 115  
 2 STUDY OBJECTIVES  
The primary objective is to assess the safety, efficacy and tolerability parameters of PRO 140 
compared to placebo in reducing HIV -1 viral load in patients on their current ART  (failing 
regimen) during the one week double- blind treatment period.  
The secondary objectives are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with optimized background therapy in patients during the 24- week 
single- arm, open- label treatment period.  
The primary efficacy endpoint will be proportion of participants with a 0.5 log
10 or greater 
reduction in HIV -1 RNA viral load from baseline at the end of the one week double -blind 
treatment period (Part 1).  
The s econdary efficacy endpoints will be proportion of participants with ≥ 0.5 log 10 reduction in 
HIV- 1 RNA viral load from baseline at the end of the 1 -week double -blind treatment period, 
stratified to each group: (a) resistance to ART drugs within three drug classes, (b) resistance to ART  drugs within two drug classes  with limited treatment option,  proportion of participants with  
≥ 1 log
10 reduction in HIV -1 RNA  viral load from baseline at the  end of  the 1-week double -blind 
treatment period (Part 1) for all patients and within each stratum, mean change from Baseline in HIV- 1 RNA levels (log
10 copi[INVESTIGATOR_014]/mL) at the end of the 1 -week double -blind treatment period  
(Part 1) for all patients and within each stratum, percentage of participants achieving HIV -1 
RNA < 400 copi[INVESTIGATOR_014]/mL at week 25, percentage of participants achieving HIV -1 RNA < 50 
copi[INVESTIGATOR_014]/mL at week 25 for all patients and within each stratum, mean change from Baseline in HIV- 1 RNA levels (log
10 copi[INVESTIGATOR_014]/mL) at week 25 for all patients and within each stratum, mean 
change from Baseline in CD4 cell count at the end of the 1 -week double -blind treatment period 
(Part 1) for all patients and within each stratum and mean change from Baseline in CD4 cell count at wee k 25 for all patients and within each stratum.  
Safety assessments include evaluation of emergence of Dual/Mixed (D/M) - and CXCR4 -tropic 
virus in patients who had exclusive CCR5- tropic virus at study entry, tolerability of repeated 
subcutaneous administration of PRO 140 as assessed by [CONTACT_19288] (using Visual Analogue Scale) and by [CONTACT_1697] –evaluation of injection site reactions, frequency of treatment- related adverse events resulting in study drug discontinuation, frequency of Grade 3 or 
4 adve rse events and frequency of treatment -emergent serious adverse events.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  43 of 115  
 3 STUDY DESIGN 
This is a Phase 2b/3, multi -center, two part study, designed to evaluate the efficacy, safety and 
tolerability of PRO 140 in conjunction with existing ART (fa iling regimen) for one week and 
Optimized Background Therapy (OBT) for 24 weeks respectively. The patient population for  
this trial are treatment -experienced patients with CCR5 -tropic virus and demonstrates evidence  
of HIV -1 replication despi[INVESTIGATOR_756425] ( or within two drug classes with 
limited treatment option).  
The study is divided into three  phases:  Screening, Treatment  and Follow- up. 
Screening Phase begins with signing of Informed Consent and lasts up to [ADDRESS_1035174] will 
enter the Treatment Phase as soon as HIV -1 viral tropi[INVESTIGATOR_8801], genotypic and/or phenotypic  
resistance results are available for review by [CONTACT_10670].  
The Treatment  phase is divided into two parts:  
• Part 1:  One-week randomized, double -blind, placebo- controlled period consisting of two 
treatment arms (PRO 140 or Placebo) along with existing ART (failed regimen).  
• Part 2:  24-week single -arm, open- label treatment period with all subjects receiving PRO 
140 along with Optimized Background Therapy (OBT) 
All subjects will continue taking their existing ART (failed regimen) during the Screening Phase 
and first week of the Treatment Phase (Part 1). After Part 1 of the Treatment Phase (1 week), all subjects will enter the 24 -week single- arm, open- label treatm ent period. During this period, all 
subjects will receive PRO 140 SC injection and OBT. 
Study participants will be  regularly  monitored for viral load following  initiation of PRO  140, and 
will cease weekly study treatment injections should they experience t reatment failure.  
Subjects who experience treatment failure at any point during the Open- Label Period of the 
Treatment Phase will undergo the Treatment Failure (TF) Visit assessments and will  be followed 
up every 4 weeks until viral suppression is achieved (i.e., plasma HIV -1 RNA levels below level 
of detection) or up to a maximum of 6 months after cessation of therapy if the treating physician 
does not feel that there is an antiretroviral regimen that will regain full viral suppression.  
Subjects who do not  experience treatment failure, will be followed up every 2 weeks for total of  
4 weeks.  
 
3.1 STUDY  CENTER (S) 
Up to 60 centers in the United  States 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  44 of 115  
 3.2 STUDY  POPULATION  
Study population includes treatment -experienced HIV -infected patients with CCR5 -tropic virus 
who demonstrates evidence of HIV -1 replication despi[INVESTIGATOR_616487] ( or 
within two drug classes with limited treatment option). The options may be limited as a result of 
drug antiviral class cross- resistance, documented treatment intolerance, documented objective 
assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity 
reactions or neuropsychiatric issues that could limit use of currently approved drugs. 
Note: Enrollment will be stratified to have HIV -[ADDRESS_1035175]  meet  all of the following criteria  to be included in the study:  
1. Males and females,  age ≥18 years 
2. Exclusive CCR5 -tropic  virus at Screening  Visit as determined  by [CONTACT_616516]® Assay  
3. Have  a history  of at least [ADDRESS_1035176] limited treatment  
option. The options may be limited as a result of drug antiviral class cross -resistance, 
documented treatment intolerance, documented objective assessments such as renal or  
hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to 
potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs. 
5. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure.  
6. Plasma HIV -1 RNA ≥ 400 copi[INVESTIGATOR_014]/mL at Screening Visit as determined by [CONTACT_616517] 1 (HIV -1) Quantitative,  RNA ([COMPANY_002] Taqman®  Real-Time  PCR)  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  45 of 115  
 and documented detectable viral load (HIV-1 RNA >50 copi[INVESTIGATOR_014]/ml) within the last 3 months 
prior to Screening Visit.  
7. Laboratory  values at Screening  of: 
a. Absolute neutrophil count (ANC)  ≥750/mm3  
b. Hemoglobin (Hb)  ≥10.5 gm/dL (male) or ≥ 9.5 gm/dL  (female)  
c. Platelets  ≥75,000 /mm3  
d. Serum  alanine transaminase (SGPT/ALT)  <5 x upper limit  of normal (ULN)  
e. Serum  aspartate transaminase (SGOT/AST)  <[ADDRESS_1035177]  
f. Bilirubin (total) < 2.[ADDRESS_1035178] unless Gilbert's disease is present or subject is receiving 
atazanavir in the absence of other evidence of significant liver disease  
g. Creatinine  ≤1.[ADDRESS_1035179]  agree to  use 2 
medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contrace ptive rings],  
and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug  
10. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by [CONTACT_11682]. 
Note:  Subjects diagnosed with  either  substance dependence or  substance abuse or any history 
of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in 
the opi[INVESTIGATOR_756426]’s 
successful completion of the study requirements. 
3.3.2 Exclusion Criteria  
Subjects meeting  any of the following  criteria will be excluded from the study:  
1. Documented CXCR4 -tropic virus or Dual/Mixed tropic (R5X4) virus as determined by 
[CONTACT_10840]- 1 tropi[INVESTIGATOR_455385].  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  46 of 115  
 2. Patients with no viable treatment options ( i.e., no fully active antiretroviral drug  
available which can be effectively combined to form a viable new OBT)  
3. Any active infection or malignancy requiring acute therapy  (with the exception of local 
cutaneous Kaposi’s sarcoma)  
Note:  Subjects infected  by [CONTACT_91292]  B virus or hepatitis  C virus  will be eligible  for the 
study if they have no signs of hepatic decompensation and meet the liver function tests 
eligibility criteria  
4.  Laboratory  test values of ≥ grade 3 DAIDS laboratory abnormality with the exception of 
the absolute CD4+ count criterion of <200/mm3 
5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study 
6. Unexplained fever or clinically significant illness within [ADDRESS_1035180] study dose.  
8. Subjects weighing < 35kg  
9. History  of anaphylaxis  to oral or parenteral  drugs  
10. History  of Bleeding Disorder  or patients  on anti-coagulant therapy 
11. 
12. Participation  in an experimental drug trial(s) within  30 days of the Screening  Visit 
13. Any known allergy  or antibodies to the  study drug or excipi[INVESTIGATOR_840]  
14. Treatment  with any of the following:  
a. Radiation  or cytotoxic chemotherapy with 30 days prior to the screening  visit 
b. Immunosuppressants within  60 days prior to the screening  visit 
c. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or 
foscarnet within 60 days prior to the screening visit 
d. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. 
Subjects on chronic steroid therapy > 5 mg/day will be excluded with the  
following exception:  
o Subjects on inhaled, nasal,  or topi[INVESTIGATOR_756427]  
15. Any other clinical condition that, in the Investigator's judgment, would poten tially 
compromise study compliance or the ability to evaluate safety/efficacy  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  47 of 115  
 [Note: Exclusion Criteria #11 was removed from protocol version 8.0. The exclusion 
criteria numbering/order is retained to maintain consistency.]  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  50 of 115  
 Note: Study treatment injections at T1, T2, T3, T7, T11, T15, T19 and T23 must be 
administered at clinic. The remaining study treatment injections may be self - 
administered by [CONTACT_616505]. 
Any time during the Open- Label Treatment Phase, if treatment failure occurs, 
Investigator will readjust antiretroviral regimen based on HIV -1 genotypic and/o r 
phenotypic drug resistance results obtained during the TF visit. Subjects will be allowed to continue PRO 140 with existing OBT regimen while waiting 
for new regimen to be constructed by [CONTACT_737]. 
Treatment failure is defined in terms of virologi c non- response and virologic rebound in 
the Open- Label Treatment Phase (Part 2) of the study:  
a) Virologic non-response is defined  as two consecutive viral load results of: 
• <0.5 log 10 copi[INVESTIGATOR_014]/mL decrease in HIV -1 RNA at Day 7 of the Open- Label 
Treatment Period . [Assessment Timepoint:T3 visit]  
• <1 log 10 copi[INVESTIGATOR_014]/mL  decrease in HIV -1 RNA at or after Week 4 of the Open -Label 
Treatment Period unless HIV -1 RNA <400 copi[INVESTIGATOR_014]/mL. [Assessment Timepoint: 
from T6 up to T25 visit] 
• Confirmed plasma HIV -1 RNA levels ≥400 copi[INVESTIGATOR_014]/ mL at Week 24 of the Open- 
Label Treatment Period [Assessment Timepoint: T25 visit]  
b) Virologic rebound is defined as two consecutive viral load results  of: 
≥1.0 log 10 copi[INVESTIGATOR_014]/mL increase in plasma HIV -1 RNA above nadir level* in the 
Open -Label Treatment Period [Assessment Timepoint: from T3 up to T25 visit] or 
*Note: This refers to “Nadir” level in the Open -Label Treatment Phase which 
starts from T2 visit  
• ≥400 copi[INVESTIGATOR_014]/mL  after suppression to <50 copi[INVESTIGATOR_014]/mL  in the Open- Label Treatment 
Period. [Assessment Timepoint: from T3 up to T25 visit] 
(3) Follow- Up Phase:  The duration of follow -up depends on whether or not subject has 
experienced treatment failure during the Open- Label Treatment Phase.  
• Subjects who experience treatment failure within Open -Label Treatment Phase will  
be followed up every 4 weeks until viral suppression is achieved (i.e., plasma HIV -1 
RNA levels below  level of  detection) or up to a maximum of  6 months after  cessation 
of therapy if the treating  physician does not feel that there is an antiretroviral regimen 
that will regain full viral suppression.  
• Subjects who do not experience treatment failure at the end of Open -Label Treatment 
Phase, will be followed up every 2 weeks for total of 4 weeks. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  51 of 115  
 Procedures to be performed during each of these study phases are described below and provided 
as a Schedule of Assessments in Table 4 -1 and Table 4 -2. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  54 of 115  
  
 
Foot Notes:  
[1] Informed consent must  be obtained  prior to patient participation in any protocol-related  activities  that are not part of routine care. 
[2] Initial evaluation  of patient  eligibility  will be performed by [CONTACT_10670].  
[3] Medical  history, past surgeries, disease  history, history of substance abuse, social history, blood transfusion history, and current therapi[INVESTIGATOR_014]  (medications  and non- 
medications).  
[4] Symptom-directed  physical examination  
[5]  The neurological assessment  tool is based  on the three question survey used by [CONTACT_604860]. (Simioni S, 2010) Additional neurological assessment modalities 
may be used as per Investigator’s discretion. 
[6] Post treatment  vital signs will be recorded at T1-3, T7, T11, T15, T19, T23, EOT  and TF visits  blood pressure, heart  rate, respi[INVESTIGATOR_1487], and temperature.)  
[7] Hemoglobin, Hematocrit (HCT), Red Blood Cells  (RBC), White  Blood Cells  (WBC)  with total and differential count, Absolute Neutrophil Count (ANC)  and platelets.  
[8] Serum Biochemistry  
Hepatic function indicators: total and direct bilirubin, alkaline  phosphatase, aspartate  aminotransferase (AST), alanine  aminotransferase (ALT), total protein, Lactate 
dehydrogenase (LDH) 
Renal  function indicators:  BUN,  creatinine  
Electrolytes: sodium, potassium, chloride, calcium and bicarbonate 
Othe r: glucose (random), cholesterol (total)  
[9] Prothrombin time (PT) and International  Normalized  Ratio  (INR)  
[10] ONLY performed on women  of childbearing potential. 
[11] Urine samples  will be tested  for color, appearance,  specific gravity, pH, protein, glucose, occult  blood,  ketones, leukocyte esterase,  nitrite,  bilirubin, urobilinogen, and 
microscopic examination of urine sediment.  
[12] Includes: CD3  %, CD4  %, CD8  %, Absolute Lymphocytes, CD3  cell count, CD4  cell count, and CD8  cell count  
[13] PK samples  for PRO  140 will be collected  prior to IP administration  at the T1, T7, T15, EOT  and TF visits.  
[14] Serum conc. of ART  Drugs prior to IP administration at the T1, T7, T15, EOT  and TF visits.  
[15] Randomization  via WebView  CTMS system  
[16] Injection Site Reaction  Assessment  as assessed  by [CONTACT_10670] (or designee) at each treatment visit that occurs at the clinic  . 
[17] Subject-perceived  injection  site pain (average pain since  last treatment)  will be assessed  using the Pain Visual  Analog Scale (VAS)  prior to each study treatment 
administration  
[18] Monogram  Biosciences  Trofile® (DNA or RNA Assay based  on viral load) 
[19] Monogram Biosciences  PhenoSense® GT (and PhenoSense Integrase and GeneSeq  Integrase testing,  if applicable)  
[20] Monogram  Biosciences  HIV- 1 PhenoSense® Entry assay  with AMD3100 (CXCR4  inhibitor drug),  Maraviroc  and PRO  140 (CCR5  inhibitor  drugs).  
[21] Quest  Diagnostics HIV-1 Coreceptor Tropi[INVESTIGATOR_756428]-1 Proviral Tropi[INVESTIGATOR_756429]  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035181] (or Legally Acceptable Representative (LAR)) will sign and date the informed 
consent form (ICF) and Health Insurance Portability Accountability Act (HIPAA) authorization (according to site policy and practices) prior to any study -related proced ures. A unique 
identification number (screening number) will be assigned to each subject who has provided written informed consent. The subject screening number will incorporate a three -digit Study 
Center number (001, 002 or 003….) and a three -digit numeri c ID assigned in successive order of 
entering the study after signing the ICF at each center, beginning with 001 at each site (e.g. 001- 001 or 002-001). 
Subject  Screening  # : XXX  - YYY  
XXX=Study  Center  YYY=Subject  Numeric  ID 
 
All study centers will be instructed to maintain the study -specific pre -screening, screening and 
enrollment logs at their sites. If a subject initially fails to meet inclusion/exclusion criteria and is later reconsidered for participation, the subject will be re -consented and assigned a new screening 
number at the time of re -screening. Subjects who fail their first screening attempt may be re - 
screened a maximum of once and may be enrolled if they are found to meet all inclusion and no exclusion criteria wh en re -screened.  
Once the ICF has been signed, screening procedures and information will be obtained to confirm subject eligibility including: 
• Detailed  medical  history (see section  7.4), 
• Detailed  history of HIV infection  and treatment  (see section  7.5), 
• Demographic information  (see section  7.3), 
• Prior and current  medications  review  (see section  7.6), 
• Physical  examination  (see section  7.7), 
• Electrocardiogram  (ECG)  (see section  7.8), 
• Body Weight & Height measurements (see section  7.10) 
• Vital Signs (see section  7.10),  
• Collection  of Blood Specimens (see section  7.11) for 
o Complete  Blood Count  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  57 of 115  
 o Biochemistry  
o Coagulation Indices [Prothrombin  time (PT) and INR]  
o Hepatitis  B surface antigen (HBsAg)  
o Plasma HIV-1 RNA  level 
o TruCount T Assay  
o HIV-1 viral tropi[INVESTIGATOR_8801] (Trofile®  DNA or RNA Assay)  
o HIV-1 Drug  Resistance Assay  
o HIV-1 PhenoSense® Entry  (Monogram BioSciences) 
o Serum pregnancy test, for female subjects of childbearing potential. Childbearing 
potential  is defined as someone who  is not surgically  sterile  or is  not more  than one 
year past complete cessation of menstrual cycles.  
o Blood sample collection  for Exploratory/Confirmatory analysis 
• Collection  of Urine  Specimen  for Urinalysis  (see section  7.11.13) 
 
All screening information will be fully documented in the subject’s medical records (i.e., source 
documents).  
• For consented subjects who do not meet eligibility criteria , a Screen Failure electronic 
Case Rep ort Form (eCRF) will be completed. The Screen Failure eCRF will contain the 
following details: the subject identification number, the date of ICF signature, 
demographic information (see  section  7.3), and the reason  for screen  failure. No  additional 
information will be required for subjects who fail screening.  
• For consented subjects who meet eligibility criteria, all required screening information  
will be transcribed onto the appropriate page of the eCRF. 
Eligible subjects that are not enrolled within [ADDRESS_1035182] screening lab 
assessments repeated, with the exception of HIV -1 viral tropi[INVESTIGATOR_8801], genotypic and/or phenotypic 
resist ance, to reconfirm eligibility.  
 
4.2 TREATMENT  PHASE  
Treatment Phase begins with an evaluation of results of laboratory samples collected during the 
Screening Phase. Subjects who meet all eligibility criteria, as per data gathered from Screening 
Phase are to b e treated. All subjects who fail to meet eligibility criteria will be considered screen 
failure and exit the study without further evaluation. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  59 of 115  
 Note:  
 Subjects may return to clinic for an additional blood draw in -between the clinic visits for 
plasma HIV -1 RNA levels, per the discretion of the Investigator. 
 Subjects who experience treatment failure at any time during the Treatment Phase will 
undergo the Treatment Failure (TF) Visit assessments and enter the Follow -up Phase of the 
study.  
 Subjects who meet any criteria (other than treatment failure) for discont inuation of study 
treatment as specified in section 5.2.1 of the protocol, will undergo End of Treatment Phase 
(EOT) Visit assessments and enter the Follow -up Phase of the study. 
 Subjects who do not experience treatment failure will enter the Follow -up Phase of the  
study at the end of 25- week Treatment Phase.  All study subjects will continue or adjust their current Optimized  Background Therapy:  
• At the end of 25- week  Treatment  Phase,  or 
• Anytime  during the  Treatment Phase, if treatment failure  occurs or  have met any  other criteria 
for discontinuation of study treatment as specified in section 5.2.[ADDRESS_1035183] treatment,  with 
weekly  visits (±  3 days) thereafter.  The first Treatment Visit (T1)  will take place as soon  as HIV - 
1 viral tropi[INVESTIGATOR_8801],  genotypic and/or phenotypic resistance results are available for review  by 
[CONTACT_10670], within 6 weeks of the Screening Visit.  
The following visits  will occur during the 25- week  Treatment  Phase:  
• T1 (First  Treatment  Administration): within  6 weeks of Screening  Visit  
• T2 (Second  Treatment Administration): 7(± 3) days from last visit 
• T3 (Third Treatment  Administration ): 7(± 3) days from last visit 
• T4 (Fourth Treatment Administration): 7(± 3) days from last visit 
• T5 (Fifth Treatment Administration ): 7(± 3) days from last visit 
• T6 (Sixth Treatment Administration ): 7(± 3) days from last visit 
• T7 (Seventh  Treatment Administration): 7(± 3) days from last visit 
• T8 (Eighth Trea tment Administration ): 7(± 3) days from last visit 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  60 of 115  
 • T9 (Ninth Treatment  Administration ): 7(± 3) days from last visit 
• T10 (Tenth Treatment Administration): 7(± 3) days from last visit 
• T11 (Eleventh Treatment Administration): 7(± 3) days from last visit 
• T12 (Twelfth Treatment Administration): 7(± 3) days from last visit 
• T13 (Thirteenth Treatment Administration): 7(± 3) days from last visit 
• T14 (Fourteenth  Treatment Administration): 7(± 3) days from last visit 
• T15 (Fifteenth Treatment Administration): 7(± 3) days from last visit 
• T16 (Sixteenth Treatment Administration): 7(± 3) days from last visit 
• T17 (Seventeenth  Treatment Administration): 7(± 3) days from last visit 
• T18 (Eighteenth Treatment Administration): 7(± 3) days from last visit 
• T19 (Nineteenth  Treatment Administration): 7(± 3) days from last visit 
• T20 (Twentieth Treatment  Administration): 7(± 3) days from last visit 
• T21 (Twenty-first  Treatment Administration): 7(± 3) days from last visit 
• T22 (Twenty-second  Treatment Administration ): 7(± 3) days from last visit 
• T23 (Twenty-third Treatment Administration ): 7(± 3) days from last visit 
• T24 (Twenty-fourth Trea tment Administration): 7(± 3) days from last visit 
• T25 (Twenty-fifth Treatment Administration): 7(± 3) days from last visit 
• End of Treatment (EOT) Visit  – 7(± 3) days from last treatment  
• Treatment Failure  (TF) Visit  – Only  if treatment  failure  occurs during the Treatment Phase  
 
4.2.1 Treatment  Visit (T1) - Part  [ADDRESS_1035184] treatment  visit,  unless otherwise 
specified:  
Pre-Treatment  
• Confirmation of eligibility criteria by [CONTACT_616522] (see section 7.2 ) 
• Neurological assessment  (see section  7.9) 
• Symptom- directed  physical examination  (see section  7.7), 
• Change in concomitant medications  (see section 7.5) 
• Any changes in medical history  since Screening  Visit (see section  7.4), 
• Collection  of Blood Specimens (see section  7.11) for 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  61 of 115  
 o Plasma HIV-1 RNA  level 
o TruCount T Assay  
o PK sample for PRO 140 
o Anti-idiotypic  antibodies to PRO 140 
o Serum  concentration of ART  drugs  
o HIV Drug  Resistance Assay  
 Note:  Blood sample for Plasma HIV -1RNA level, TruCount T Assay and HIV -1 Drug 
Resistance Assay will be collected at SV, T1, T2, T3, T7, T11, T15, T19, T23, EOT and 
TF visits.  
 Note: PK sample for PRO 140 and Anti -idiotypic antibodies to PRO 140 will be 
performed at T1, T7, T15, EOT and TF visits 
 Note: Serum concentration for ART will be performed at T1, T7, T15, visits, EOT and 
TF visits, as well as any Unscheduled Visit within the Treatment Phase as per 
discretion of the Investigator.  
• Urine  Pregnancy  Test (see section  7.11.6) 
• Randomization (see section  7.12) 
Administration  of study  treatment  [PRO  140 or placebo]  
Study treatment  will be administered  weekly  as a subcutaneous injection  in the abdomen.  
Subjects will receive the study treatment delivered as two 1  mL injections on opposite  sides of  the 
abdomen.  
Note:  All study treatments (PRO 140 or placebo) must be administered by a qualified medical 
professional (MD, DO, PA, LPN, LVN, NP, or RN) or self -administered by [CONTACT_756442]. 
Post-Treatment  
• Injection  Site Reaction  Assessment  (see section  7.14) 
 Note: To assess injection site reactions, the investigator will use the DAIDS AE 
grading table (refer to section 17.3 ). 
• Assessment  of Adverse Events (AE)  (see section  9) 
• Vital Signs (see section  7.10) will be assessed  within  15 minutes of study treatment 
administration.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  62 of 115  
 Note: Investigator should determine the Optimized background therapy (OBT) regimen based on 
genotypic and/or phenotypic results obtained during Screening Phase and provide the appropriate 
prescription to the study subject at Treatment Visit 1 (T1).  
OBT is a standard-of- care regimen comprised of 3 or more antiretroviral agents selected by [CONTACT_616506]/or phenotypic assessments. The use of another experimental agent (e.g., ibalizumab)  to create a viable HIV suppressive OBT regimen in 
certain subjects with severely limited approved and available therapeutic options will be allowed with the prior approval from sponsor. 
4.2.2 Treatment  Visit-2 (T2) to Treatment  Visit -25 (T25) - Part  2 of Treatment  Phase  
The follow ing assessments will be performed  at each visit,  unless otherwise  specified:  
• Assess for any Adverse Events and changes in Concomitant medications  (see section  9 
and 7.5),  
• Symptom- directed  physical examination  (see section  7.7), 
• Neurological Assessment  (see section  7.9) 
 Note:  Neurological assessment  will be performed  at T3, T7, T11, T15, T19, T23 visits 
• Vital Signs (see section  7.10) 
 Note: Post-treatment vital signs will be assessed within 15 minutes following study 
treatment administration when performed inside clinic.  
• Collection  of Blood Specimens (see section  7.11) for 
o Plasma HIV-1 RNA  level 
o TruCount T Assay  
o HIV-1 Drug  Resistance Assay  
o PK sample for PRO 140 
o Serum  concentration of ART  drugs  
o Anti-idiotypic  antibodies to PRO 140 
 Note:  Blood sample for Plasma HIV -1RNA level, TruCount  T Assay, and HIV-1 Drug 
Resistance Assay will be performed at SV, T1, T2, T3, T7, T11, T15, T19, T23, EOT 
and TF visits 
 Note: PK sample for PRO 140 and Anti -idiotypic antibodies to PRO 140 will be 
performed at T1, T7, T15, EOT and TF visits 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  63 of 115  
  Note: Serum concentration for ART will be performed at T1, T7, T15, visits, EOT and 
TF visits, as well as any Unscheduled Visit within the Treatment Phase as per 
discretion of the investigator. 
 
• Study Treatment  Administration  (PRO 140) 
• Injection  Site Reaction  Assessment  (see section  7.14) 
 Note: To assess in jection site reactions, the investigator will use the DAIDS AE 
grading table (refer to section 17.3 ). 
• Subject- perceived  Injection  Site Pain Assessment  (see section  7.15) 
 Note: Subject- perceived injection site pain will be assessed using the Pain Visual 
Analog Scale (VAS) prior  to study treatment administration assessing average pain at 
injection site since last treatment.  
4.2.3 End of Treatment  (EOT)  Visit  
The following assessments will be performed  for subjects who do not experience treatment  failure 
at any time during the Treatment Phase:  
• Assess for any Adverse Events and changes in Concomitant medications  (see section  9 
and 7.5),  
• Complete  Physical Examination  (see section  7.7), 
• Vital Signs (see section  7.10),  
• Neurological Assessment  (see section  7.9), 
• Subject- perceived  Injection  Site Pain Assessment  (see section  7.15),  
• Collection  of Blood Specimens (see section  7.11) for 
o Plasma HIV-1 RNA  level 
o TruCount T Assay 
o Complete  Blood Count  
o Biochemistry  
o Anti-idiotypic  antibodies to PRO 140 
o PK sample for PRO 140 
o Serum  Conc. of ART  Drugs  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  64 of 115  
 4.2.4 Treatment  Failure  (TF)  Visit  
Treatment failure is defined in terms of virologic non -response and virologic rebound in Part 2 of 
the Treatment Phase:  
(1) Virologic non-response is defined  as two consecutive viral load results of: 
• <0.5 log 10 copi[INVESTIGATOR_014]/mL decrease in HIV -1 RNA at Day 7 of the Open -Label Treatment 
Period. [Assessment Timepoint:T3 visit]  
• <1 log 10 copi[INVESTIGATOR_014]/mL decrease in HIV -1 RNA at or after Week 4 of the Open -Label 
Treatment Period unless HIV -1 RNA <400 copi[INVESTIGATOR_014]/mL. [Assessment Timepoint: from T6  
up to T25 visit] 
• Confirmed plasma HIV -1 RNA levels ≥400 copi[INVESTIGATOR_014]/mL at Week 24 of the Open -Label 
Treatment Period. [Assessment Timepoint: T25 visit]  
(2) Virologic rebound is defined as two consecutive viral load results  of: 
≥1.0 log 10 copi[INVESTIGATOR_014]/mL increase in plasma HIV -1 RNA abo ve nadir level* in the Open- 
Label Treatment Period [Assessment Timepoint: from T3 up to T25 visit] or 
*Note: This refers to “Nadir” level in the Open -Label Treatment Phase which starts from 
T2 visit.  
• ≥400 copi[INVESTIGATOR_014]/mL  after suppression  to <50 copi[INVESTIGATOR_014]/mL in the Open -Label  Treatment  Period.  
[Assessment  Timepoint: from T3 up to T25 visit]  
 
The following assessments will be  performed for subjects who experience treatment failure at any 
time during the Treatment Phase : 
• Assess for any Adverse Events and changes in Concomitant medications  (see section  9 
and 7.5),  
• Complete  Physical Examination  (see section  7.7), 
• Vital Signs (see section  7.10),  
• Neurological Assessment  (see section  7.9), 
• Subject-perceived  Injection  Site Pain Assessment  (see section  7.15),  
• Collection  of Blood Specimens (see section  7.11) for 
o Plasma HIV-1 RNA  level 
o TruCount T Assay  
o Complete  Blood Count  
o Biochemistry  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  65 of 115  
 o HIV Drug  Resistance Assay  
o HIV PhenoSense Entry® Assay  
o HIV Trofile®  Assay  
o Anti-idiotypic  antibodies to PRO 140 
o PK sample for PRO 140 
o Serum  Conc. of ART  drugs  
o Blood sample collection  for Exploratory/Confirmatory analysis 
• Change in Optimized Background Therapy based on genotypic and phenotypic results 
obtained at TF visit.  
 
4.[ADDRESS_1035185]  experiences treatment  failure.  
• Subjects who experience treatment failure within Open- Label Treatment Phase will be 
followed up every 4 weeks until viral suppression is achieved (i.e., plasma HIV -1 RNA 
levels below level  of detection)  or up to a maximum of 6 months after cessation  of therapy 
if the treating  physician does  not feel that there  is an antiretroviral regimen  that will regain 
full viral suppression.  
• Subjects who do not experience treatment failure at the end of Open -Label Treatment 
Phase, will be followed up every 2 weeks for total of 4 weeks. 
4.3.1 Follow- Up Visits  
The following assessments will be performed  at each follow -up visit,  unless otherwise  specified:  
• Assess for any Adverse Events and changes in Concomitant medications (see section 9 
and 7.5),  
• Symptom- directed  physical examination  (see section  7.7), 
• Vital Signs (see section  7.10),  
• Collection  of Blood Specimens (see section  7.11) for 
o Plasma HIV-1 RNA  level 
o TruCount T Assay  
o Anti-idiotypic antibodies to PRO 140 (only at Treatment Failure - FU1 and Non 
Treatment Failure - FU2)  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  66 of 115  
 4.4 UNSCHEDULED  VISITS  
In the event that the patient returns to clinic at a time other than a regularly  scheduled study visit, 
the visit will be regarded as an unscheduled visit. Assessments at unscheduled visits are at the 
discretion of the Investigator.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035186] COMPLETION  
 
• A subject who completes the Open- Label Treatment Phase (without treatment failure) 
and 4- week Non -Treatment Failure Follow -Up Phase will be considered as having 
completed the study. 
• A subject who experiences t reatment failure during  the Treatment Phase, undergoes the 
Treatment Failure (TF) Visit assessments and is followed up until viral suppression is 
achieved or up to a maximum of [ADDRESS_1035187], study treatment or observations were discontinued, the reason(s) will be recorded. 
The Investigator can discontinue a subject  at any time if it is considered medically  necessary.  
In addition, subjects WILL be withdrawn from the study, in consultation with the Medical 
Monitor and the Investigator, if any of the following are met:  
• A subject  is significantly  non-compliant with the requirements of the protocol.  
• The investigator determines  that it is in the best interest of the subject.  
• Subject chooses to withdraw  or is withdrawn  due to an adverse event  
• A subject  becomes pregnant  
Note : The pregnancy will be followed to term for safety follow -up. Relevant safety 
information collected after the study has completed will be reported as supplemental 
information.  
• Discontinuation of study by [CONTACT_756443], in consultation with the Medical Monitor  
and the Investigator, any of the following are met:  
• A subject  is treated  with a  prohibited medication.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  68 of 115  
 • Major  protocol violation  
 
5.2.1 Discontinuation  of Study  Treatment  
Discontinuation of study treatment (PRO  140) and continuation of HAART  as per standard of 
care is recommended if:  
• Subject experiences treatment failure  
Defined in terms of virologic non- response and  virologic rebound in the Open-Label 
Treatment Phase (Part 2) of the study:  
(1) Virologic non-response  is defined as two consecutive  viral  load results of: 
• <0.5 log 10 copi[INVESTIGATOR_014]/mL decrease in HIV -1 RNA at Day 7 of the Open-Label 
Treatment Period. [Assessment Time point:T3 visit]  
• <1 log 10 copi[INVESTIGATOR_014]/mL decrease in HIV -1 RNA at or after Week 4 of the Open-Label 
Treatment Period unless HIV -1 RNA <400 copi[INVESTIGATOR_014]/mL. [Assessment Timepoint: 
from T6 up to T25 visit] 
• Confirmed plasma HIV -1 RNA levels ≥400 copi[INVESTIGATOR_014]/mL at Week 24  of the Open- 
Label Treatment Period. [Assessment Timepoint: T25 visit]  
(2) Virologic rebound is defined as two consecutive viral  load results of: 
• ≥1.0 log 10 copi[INVESTIGATOR_014]/mL increase in plasma HIV -1 RNA above nadir level * in the  
Open -Label Treatment Period [Assessment Timepoint: from T3 up to T25 visit] or 
*Note: This refers to “Nadir” level in the Open -Label Treatment Phase which starts from T2 
visit 
• ≥400 copi[INVESTIGATOR_014]/mL after suppression to <50 copi[INVESTIGATOR_014]/mL in the Open- Label Treatment 
Period. [Assessment Timepoint: from T3 up to T25 visit] 
 
Note:  Subjects will be allowed  to continue PRO 140 with existing  OBT  regimen  while 
waiting for new regimen to be constructed by [CONTACT_737]. 
 
• Develops AIDS -defining conditions as specified in Appendix I ( Section 17.1) under which 
subject is unable to continue treatment with study drug (PRO 140), or subject require 
treatment with prohibited concomitant medications.  
• Shows signs or symptoms of clinically  significant immunosuppression  
• Subject or the subject’s clinician wishes to adjust OBT (except in the event of toxicity 
management).  
• Subject becomes pregnant. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  69 of 115  
 5.2.2 Data  Collected  for Withdrawn Subjects  
Patients  may withdraw  from the study or discontinue study treatment at any time; 
however, CytoDyn is dedicated to minimizing missing data in this study. It is therefore 
suggested that all patients, regardless of whether they continue to receive study treatment, 
continue within  the study. 
Investigators considering discontinuing study treatment should contact [CONTACT_756444]. Patients  who have study treatment discontinued will continue 
to be followed, per protocol, whenever possible. Patients who have  study treatment 
discontinued due to a serious adverse event will  be followed  until resolution  or stabilization  of 
the event.  
In the event that a subject is withdrawn from the study at any time du e to an adverse event or 
serious adverse event (SAE), the procedures stated in Section 9.1.[ADDRESS_1035188] number, demographics and reason for screen failure will 
be recorded.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035189]  STORAGE  
Study drug will be shipped at 2°C to 8°C (refrigerated [36°F to 46°F]) to the investigator’s site. Upon receipt at the site, the responsible site staff or pharmacist should verify the integrity of the 
vials. Study drug should be  stored at 2°C to 8°C (refrigerated [36°F  to 46°F]). The contents of the 
vial should appear as a clear to opalescent, colorless to yellow solution; fine translucent particles may be present. This is normal. 
The investigator must maintain an accurate record of the shipment, storage, and dispensing of the study drug in a drug accountability log. An accurate record including the date and amount of  
study drug dispensed to each subject must be available for inspection at any time. A study CRA assigned to monitor  the investigational site will review  these documents once  study drug has been 
received by [CONTACT_2727]. Study drug will be accounted for on an ongoing basis during the study. 
 
6.[ADDRESS_1035190]  ADMINISTRATION  
Guidelines for dose preparation  can be found in the pharmacy manual.  
PRO 140 or placebo will be provided to the administering personnel in single -use syringes 
prepared from vials of study drug stored at 2 -8°C at the site pharmacy prior  to use. Each of two 
syringes is filled to deliver 1.0 mL of study drug. 
Equivalent volumes of study drug will be administered subcutaneously on opposite sides of the 
abdomen.  
A 25-guage needle should be used to remove IP from  vial and for administration  to subjects.  
IP should be administered slowly over 15 seconds per mL. IP should not be kept in syringe for longer than 60 minutes.  
Following each SC delivery  of drug, careful examination will be  made to assess the appearance of 
any study drug Injection Sit e Reactions (ISRs) as described in Section 17.3. 
All doses of study drug will be prepared by [CONTACT_756445]  a qualified medical  professional 
(MD, DO, PA, LPN, LVN, NP, or RN) or self -administered by [CONTACT_756446].  
Note: It is preferred that the  same injection site be used throughout the  study. At the  same time, it 
is not recommended  to inject the study drug into areas where  skin shows signs of a previous  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035191] which includes each quantity dispensed, identification of the staff member/subject to whom dispensed, the date of dispensing, the intended study participant, and the identification of the preparer. All used and unused study kits will be retained by [CONTACT_756447]. Instructions will be provided by [CONTACT_26477]. 
 
6.[ADDRESS_1035192] not destroy any drug labels or any partially used or unused drug supply until instructed by [CONTACT_1034]. At the conclusion of the study and as appropriate during the course of the study, the investigator will return all used and unused drug containers and drug labels to the drug distributor as directed  by [CONTACT_1034]. A copy of the completed  drug disposition form will  be 
sent to CytoDyn, Inc. or to its designee. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035193] adhere to Good Clinical Practice (GCP). The Investigator, or 
designee, must fully  inform subjects of all pertinent aspects of  the study. Before  informed consent 
may be obtained, the  Investigator, or a person designated by [CONTACT_737], must provide the 
subject ample time and opportunity to inquire about details of the study and to decide whether or not to participate in the trial. All questions about the trial must be answered to  the satisfaction of 
the subject. Prior to the subject’s participation in the trial, the written informed consent must be signed and personally  dated  by [CONTACT_756448]. Authorization for release  of protected health information must also be  obtained, as per 
local policies.  
 
7.2 ASSESSMENT  OF ELIGIBILITY  
During the Screening Phase and at T1 Visit (prior to treatment administration), the Investigator must assess a subject’s continued suitability and elig ibility for the trial. The Inclusion and 
Exclusion criteria of this Protocol are described in Sections 3.3.[ADDRESS_1035194] will be a screen failure.  
 
7.3 DEMOGRAPHIC  INFORMATION  
For the purposes  of this study, demographic information  will include:  
• Dates of ICF signature  
• Date  of birth 
• Gender  
• Race (American  Indian/Alaskan Native,  Asian,  Black/African  American,  Native 
Hawaiian/Pacific Islander, Caucasian, or other)  
• Ethnicity  (Hispanic/Latino  or Not Hispanic/Latino)  
 
7.4 MEDICAL  HISTORY  
A medical  history  will be recorded  during the Screening Phase  and will include:  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  77 of 115  
 • All ongoing medical conditions  
• Disease history  (HIV),  history  of substance abuse,  social  history,  blood transfusion  history 
and any past surgeries  
• All previously resolved  medical  conditions related  to HIV or which  are relevant  in the 
judgment of the Investigator  
• Any prior medical conditions that have resolved  within  the last year 
Events that emerge prior to the  first treatment (T1) will be  recorded in the medical history  and not 
as AEs. Aside from being used to determine subject eligibility, this information will permit the  
Investigator to record the nature, duration and severity of any ongoing baseline medical  
conditions prior to the patient’s receiving investigational product (IP) treatment.  
Medical  histories  will be recorded  using the body system  categories outlined below:  
• Cardiovascular  • Lymphatic  
• Respi[INVESTIGATOR_696]  • Hematologic  
• Gastrointestinal • Immunologic  
• Renal  • Dermatologic  
• Hepatic  • Psychiatric  
• Neurological  • Genitourinary  
• Endocrine  • Other  
 
For each relevant  history,  the following will be documented:  
• Disease/disorder/condition  
• Date  of diagnosis  
• History  status (resolved  or ongoing)  
 
7.5 HIV HISTORY  
A detailed  HIV history  will be recorded  during the Screening  Phase and will include:  
• Date  of diagnosis  
• Most  recent  viral load and CD4  count  
• Nadir  CD4  and peak  viral load, if known  
• ART -related  history  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  78 of 115  
 o Current and previous ART  regimens  
o Date  of initiation  of ART  
o Reasons for changes in ART  
o Previous adverse drug reactions,  including hypersensitivity reactions  to prior 
therapi[INVESTIGATOR_014]  
o Challenges with adherence to therapy 
o History  of drug resistance,  if known  
o Opportunistic infections,  malignancies,  and previous adverse  reactions to drugs 
used for opportunistic infections prophylaxis 
 
7.6 PRIOR / CONCOMITANT  MEDICATIONS  AND NON-STUDY TREATMENTS  
A complete  history  of antiretroviral therapi[INVESTIGATOR_756430].  
In addition to this, all other medications and therapi[INVESTIGATOR_616493] [ADDRESS_1035195] be questioned at each study visit concerning any new medications or changes in current medications including over- the-counter medication. 
For each medication  and non-study treatment,  the following  will be documented:  
• Medication/treatment  name  (generic  name [CONTACT_756458])  
• Dose,  unit, and frequency of dosing (individual dosages,  not total daily  dose).  
o Note:  Each new dose of medication should be recorded as a separate entry, with 
the exception of medications that are given on a sliding scale. For these, it is 
acceptable to enter the range of the dosage, including the start and stop dates for 
which the specified dosage range was used. 
• Route of dosing  
• Indication  for use 
• The start date 
• The stop date (if medication/therapy  is not ongoing)  
Please refer to Exclusion Criteria (Section 3.3.2) for a list of prohibited treatments and/or 
procedures. All other medications  that are appropriate for the care of the subject  may be 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035196]  
2. Use of oral or parenteral corticosteroids (>5 mg/day) is NOT allowed during the study, with 
the following exceptions: 
o Use of chronic  systemic corticosteroids at replacement doses (e.g., < 5mg/day prednisone) 
AND use of inhaled, nasal, or topi[INVESTIGATOR_8826] a re allowed.  
o Use of short course of systemic corticosteroids (Medrol pack) after T2 will only be 
allowed with prior approval from the sponsor. 
3. Use of radiation or cytotoxic chemotherapy, immunosuppressants and immunomodulating 
agents (e.g., interleukins, interferons) or agents with known anti -HIV activity (i.e., 
hydroxyurea, foscarnet) are NOT allowed during the study. 
4. Use of any non- FDA approved/investigational therapy  
 
7.6.2 Allowable  Medications and Therapi[INVESTIGATOR_756431]/therapi[INVESTIGATOR_756432] d and, in the judgment of the 
Investigator, are required for proper medical care of the subject may be prescribed.  
 
7.7 PHYSICAL  EXAMINATION  
The complete  physical examination  will include routine  examinations for the following:  
• General  Appearance  
• Head,  Ears,  Eyes,  Nose,  Throat (HEENT)  
• Lymph Nodes  
• Heart/Cardiovascular  abnormalities  
• Respi[INVESTIGATOR_696]  
• Abdomen  
• Genitourinary  
• Musculoskeletal  and Extremities  
• Neurologic abnormalities  Dermatologic  abnormalities  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  80 of 115  
 • Any other body system for which an abnormality  is noted and which, in the opi[INVESTIGATOR_684], is relevant to the safety of the subject or could impact safety or efficacy 
results for the subject; i.e., the abnormality is clinically significant (CS).  
Each abnormal ity will be recorded and the Investigator will record an assessment of its clinical 
significance.  
The complete physical examination will be conducted at the Screening Visit (SV), End of 
Treatment (EOT) Visit, and at Treatment Failure (TF) Visit. Only symptom- directed physical 
examination will be performed at treatment and follow -up visits conducted within the clinic, and 
at unscheduled visits within the Treatment and Follow-up Phases. 
 
7.8 ELECTROCARDIOGRAM  
A 12 -lead ECG will be conducted at the Screening Visit (SV) results will be evaluated by [CONTACT_3786]. The following parameters will be recorded: ventricular rate (beats per minute), PR interval (msec), QRS interval (msec), QT interval (msec), and QTc interval (msec). Additionally, the investigator will record the overall results of the ECG reading as either normal or abnormal, and as either not clinically significant or clinically  significant. If abnormalities are observed, each 
will be recorded. 
 
7.9 NEUROLOGICAL  ASSESSMENT  
Neurological assessment will be performed by [CONTACT_079] (or delegated personnel) or a Neurologist at Treatment Visits 1, 3, 7, 11, 15, 19 and 23 (T1, T3, T7, T11, T15, T19, T23), End of Treatment (EOT) and at Treatment Failure (TF) Visit.  
The neurological assessment tool is based on the three question survey used by [CONTACT_604860]. 
[Simioni S, 2010]. Refer  to section  17.4 for further details.  Additional assessment  modalities  can 
be used for further assessment as per Investigator’s discretion.  
 
7.10 VITAL  SIGNS  (INC. HEIGHT  AND WEIGHT ) 
Vital signs will be collected  at all study visits  performed  at the clinic.  Vital signs collected  during 
the Treatment Phase will be performed post -treatment, assessed within 15 minutes following  
study treatment administration. 
The following vital signs  will be collected  at all visits,  unless otherwise  stated:  
• Height (at Screening  Visit) 
• Weight (at SV, EOT  and TF visits) 
• BMI  (derived  from  the height and weight measurements;  at SV, EOT  and TF visits)  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  81 of 115  
 • Seated  blood pressure (taken  after the subject  has been  seated  for at least 5 minutes)  
• Heart  Rate 
• Respi[INVESTIGATOR_756433] 
• Temperature  
 
7.11 CLINICAL  LABO RATORY  ASSESSMENTS  
Blood and urine samples will be collected  according to the time points in the schedule of  
assessments for analysis of the following parameters:  
7.11.1 Routine  CBC 
• Frequency of testing : At Screening  Visit,  End of Treatment  Phase Visit or Treatment 
Failure Visit  
• Includes hemoglobin, hematocrit  (HCT),  red blood cell (RBC)  count, white  blood cell 
(WBC)  count, WBC differential count (%), absolute  neutrophils count and platelets count. 
7.11.2 Biochemistry  
• Frequency of testing : At Screening  Visit,  End of Treatment  Phase Visit or Treatment 
Failure Visit  
• Biochemistry  profile  includes assessment  of 
Hepatic function  indicators: total and direct  bilirubin,  alkaline  phosphatase,  aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), total protein, LDH  
Renal  function indicators:  BUN,  creatinine  
Electrolytes:  sodium, potassium, chloride,  calcium  and bicarbonate 
Other: glucose (random), cholesterol (total)  
7.11.3 PK sample  for PRO 140 
 Frequency of testing: At the  T1, T7, T15, EOT  and TF visits.  
 
7.11.4 Anti -idiotypic  antibodies  to PRO  140 
• Frequency of sample collection* : At the T1, T7, T15, EOT and TF visits in addition to 
Treatment Failure Follow -up Visit 1 (TF -FU1) and Non- Treatment Failure Follow -up 
Visit 2 (NTF -FU2)  
*Note:  Sera will be collected  from study subjects and stored  at -80oC for future analysis.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035197] 
• Frequency of testing : At Screening  Visit 
• Only for female subjects of childbearing potential. Childbearing potential is defined as 
someone who is not surgically sterile or is not more than one year past complete cessation 
of menstrual cycles.  
7.11.[ADDRESS_1035198] 
• Frequency of testing : At Treatment  Visit  [ADDRESS_1035199] treatment  administration  
• A urine sample will be collected from female subjects of childbearing potential. This test 
will be performed at the study site using a commercially available kit.  
7.11.7 Plasma  HIV -1 RNA level  and TruCount  T Assay  
• Frequency of testing : At SV, Treatment Visits 1,  2, 3, 7, 11, 15, 19 and 23, as well as EOT 
and TF visits. In addition, blood sample will also be collected at all Treatment Failure 
Follow-up (TF- FU) Visits  or Non- Treatment Failure Follow -up (NTF- FU) Visits . 
• To assess  antiretroviral therapeutic response to PRO  140 
Note: Plasma HIV -1 RNA level will be measured using Human Immunodeficiency Virus 1 
(HIV -1), Quantitative, RNA (Abbott RealTime) test.  
TruCount T Assay includes measurement of Absolute Lymphocytes, CD3 cell count, CD4 
cell count, CD8 cell count, CD3%, CD4% and CD8% 
7.11.8 HIV -1 Trofile®  Assay  
• Includes:  
a. Trofile® RNA Assay  
b. Trofile® DNA Assay  
Trofile® RNA is the primary assay used to assess HIV -1 co- receptor tropi[INVESTIGATOR_616496]. 
However, Trofile ® DNA can be used at the discretion of the Investigator when last 
recorded viral load is less than 1000 copi[INVESTIGATOR_014]/mL. 
• Frequency of testing : At SV and TF visits  
 
7.11.9 HIV -1 Drug  Resistance Assay  
• Includes:  
a. PhenoSense® GT 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  83 of 115  
 b. PhenoSense Integrase and GeneSeq  Integrase testing  
PhenoSense® GT is a combination resistance test for three classes of antiretroviral drugs 
(i.e., nucleoside/nucleotide, non- nucleoside, and protease inhibitors), that provides both 
phenotypic and genotypic  results from the  same  blood sample (viral load ≥500 copi[INVESTIGATOR_014]/ml).  
PhenoSense Integrase and GeneSeq Integrase testing will be additionally performed if subject has past exposure to an integrase or in cases where complex drug resistance patterns is known or suspected. 
• Frequency of sample collection : At SV, T1, T2, T3, T7, T11, T15, T19, T23 and TF 
Samples for PhenoSense® GT (and PhenoSense Integrase and GeneSeq Integrase testing, if collected) during visits T1, T2, T3,  T7, T11, T15, T19, and T23 will be  stored at Lab and 
will be analyzed only if subject experiences Trea tment Failure.  
7.11.10 HIV -1 PhenoSense®  Entry  assay  
• Frequency of testing : At SV and TF visits  
• With AMD3100 (CXCR4 inhibitor drug), Maraviroc and PRO 140 (CCR5 inhibitor 
drugs).  
7.11.11 Serum  Concentration of ART drugs  
• Frequency of sample  collection : At Treatment  Visits  1, 7, 15, EOT  and TF. 
• Sample collected at T1 visit is to identify serum concentration for ART drugs (failing 
regimen) at the time of first study dose while sample collected at T7, T15, EOT and TF 
visit is to confirm subject compliance to OBT regimen  during Part 2 of the Treatment 
Phase.  
7.11.12 Blood sample  collection  for Exploratory/Confirmatory analysis  
• Includes:  
a. HIV-[ADDRESS_1035200] variable (V3) loop of the HIV -1 gene, the primary determinant of 
viral tropi[INVESTIGATOR_8801]. The next -generation DNA sequencing (ultradeep sequencing [UDS]) is 
performed if standard sequencing detects only CCR5 virus. HIV -[ADDRESS_1035201] is used when the plasma viral load is <1000 copi[INVESTIGATOR_014]/mL. 
• Frequency of testing: At SV and TF visits  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  84 of 115  
 7.11.13 Urinalysis  
• Frequency of testing : At the Screening  Visit 
• Urine samples will be tested f or color, appearance, specific gravity, pH, protein, glucose, 
occult blood, ketones, leukocyte esterase, nitrite, bilirubin, urobilinogen, and microscopic 
examination of urine sediment  
All laboratory  reports will be reviewed  by [CONTACT_737].  
Post-treatment abnormal results that are considered by [CONTACT_616527]. If the Investigator judges it necessary, testing  may be repeated 
in order to make the determination of clinical significance. Validated, quality -controlled 
laboratory data will be transferred to the main database for analyses.  
 
7.12 RANDOMIZATION  
Subjects who are eligible to participate in the trial will be randomized to one of the treatment 
groups via IWRS (Interactive Web Based Randomization System) at the T1 Visit prior to IP administration. The randomization will be central and will use mixed b lock size of 2 and 4 with a 
1:1 ratio of Active Treatment to Control Treatment to ensure even distribution of Active and 
Control subjects. 
Prior to randomization, subjects will be stratified based on degree of ART drug resistance as 
follows:  
• Resistance to ART  drugs within three  drug classes.  
• Resistance to ART  drugs within  two drug classes  with limited  treatment  option.  
Centers will be limited to a maximum enrollment of [ADDRESS_1035202]  ADMINISTRATION  
Refer  to Section  6.4 for details.  
 
7.14 INJECTION  SITE REACTION  ASSESSME NT 
At each treatment visit that occurs at the clinical site, an injection site reaction assessment will be made for the current and previous injection sites.  Injection site reaction assessments are recorded 
by [CONTACT_737] (or designee) starting after the  first injection is given. Refer to sections 9.1.8  
and 17.3 for more details.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  85 of 115  
 7.15 PAIN ASSESSMENT USING  VISUAL ANALOG  SCALE (VAS)  
Tolerability of repeated subcutaneous administration of PRO [ADDRESS_1035203] -perceived injection site pain using the Pain Visual Analog Scale (VAS). 
This assessment will be performed each time subjects arrive to the clinic fo r the study visit.  
Beginning at Treatment Visit 2, subjects will be asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in 
length) anchored by [CONTACT_616528], “no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The subject marks on the line or 
by [CONTACT_241861] a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by [CONTACT_616529]- hand end of  
the line to the point that the patient marks. 
 
 
Figure  7-1:  Visual  Analog Scale  
 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  86 of 115  
 8 STATISTICAL CONSIDERATIONS  
This section presents general information about statistical considerations and concepts such as 
statistical power, sample size, and a brief discussion on analysis methodology, as well as some data conventions. Detailed descriptions of the statistical analysis methods and data conventions that will be used in this study will be in a separate document; i.e., the Statistical Analysis Plan (SAP).  
 
8.1 TREATMENT  GROUPS  
This is a comparator study, PRO 140 versus placebo. All eligible subjects will receive a single 
dose of study treatment [PRO 140 or placebo SC injection] within 6 weeks of Screening Visit, 
followed by [CONTACT_96553] 140 as a 350 mg subcutaneous injection weekly for up to 24 weeks. 
 
8.2 DESCRIPTION  OF STUDY ENDPOINTS  
8.2.1 Primary  Efficacy  Endpoints  
The primary efficacy endpoint for this study is proportion of participants with a ≥ 0.[ADDRESS_1035204] procedure will be used for the secondary endpoints. The 
order of the endpoints will be as follows: 
1. Proportion of participants with ≥ 0.5 log 10 reduction in HIV -1 RNA viral load from 
baseline at the end of the 1 -week double-blind treatment pe riod, stratified to each group: 
a. resistance to ART  drugs within  three  drug classes,  
b. resistance to ART  drugs within  two drug classes with limited  treatment option.  
2. Proportion of participants with ≥ 1 log 10 reduction in HIV -1 RNA viral load from baseline 
at the end of the 1 -week double -blind treatment period for all patients and within each 
stratum 
3. Mean change from Baseline in HIV -1 RNA levels (log 10 copi[INVESTIGATOR_014]/mL) at the end of the 1 - 
week double- blind treatmen t period for all patients and within each stratum 
4. Percentage of participants achieving HIV -1 RNA < 400 copi[INVESTIGATOR_014]/mL at week 25 for all 
patients and within each stratum  
5. Percentage of participants achieving HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at week 25 for all 
patients and within each stratum  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  87 of 115  
 6. Mean  change from  Baseline  in HIV-1 RNA levels (log 10 copi[INVESTIGATOR_014]/mL)  at week  25 for all 
patients and within each stratum  
7. Mean  change from  Baseline  in CD4  cell count at the end of the 1-week  double-blind 
treatment period for all patients and within each stratum  
8. Mean change from Baseline in CD4 cell count at week 25 for all patients and within each 
stratum 
8.2.3 Safety  Assessments  
Safety  measurements will include:  
• Emergence of Dual/Mixed (D/M) - and CXCR4 -tropic virus in patients who had exclusive 
CCR5 -tropic virus at study entry. 
• Tolerability of repeated subcutaneous administration of PRO 140 as assessed by [CONTACT_103607] (using Visual Analogue Scale) and by [CONTACT_1697]- evaluation of injection site 
reactions.  
• Frequency of treatment -related  adverse events resulting  in study  drug discontinuation  
• Frequency of Grade  3 or 4 adverse events as defined  by [CONTACT_756449] 
• Frequency of treatment –emergent  serious adverse events  
 
8.[ADDRESS_1035205] a total of 50 subjects (25 per treatment group) 
randomized and complete the clinical trial.  
The nQuery 6.01 is used for this sample size calculation. The sample size calculation is based on the assumption that the proportion of participants with ≥ 0.5 log
10 reduction in HIV -1 RNA viral 
load from baseline at Week 1 during the double -blind treatmen t period is 90% for the PRO 140 
group vs 35% for the Placebo group. 
Note: Response rate of 90% is estimated for the PRO 140 group on the basis of results from 
PRO140 2101 study wherein 90% of participants with CCR5- tropic virus achieved ≥ 0.5 log 10 
reducti on in HIV -1 RNA viral load in one week from baseline. 
Under the above assumptions, 25 subjects per treatment group will be required to meet the Type I 
error rate of 0.05 and more than 90% power; for a total of 50 subjects for the clinical trial.  
 
8.4 RANDOMIZA TION  AND BLINDING  
This trial is a two part treatment phase study  with a  one- week randomized, double -blind, placebo - 
controlled period, followed by a 24- week open label, single arm treatment period.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  88 of 115  
 Randomization will be conducted via a Web based system, and the process for the blinding 
requirements will be outlined in the study randomization plan. Resistance to ART drugs at the 
time of randomization will be used as a stratification factor to ensure balance between each treatment group in this stratum.  
 
8.5 INTERIM ANALYSIS  
An efficacy Interim Analysis (IA) will be conducted when [ADDRESS_1035206] the 
integrity of the trial.  The details of the IA, including the below bullet points, are included in the 
Statistical Analysis Plan (SAP) for the study.  
• The goals of the IA  
• IA procedures for data preparation  
• IA procedures conduct of the analysis 
• Data  to be shared  with the DMC 
• Information  to be shared  with the sponsor after the IA 
• The stoppi[INVESTIGATOR_1877] 
• Protection  of Type I error  rate and adjustments  
 
8.6 GENERAL  STATISTICAL  CONSIDERATIONS  
8.6.1 Analysis Populations  
[IP_ADDRESS] Intent -to-Treat  Population  
The Intent -to-Treat (ITT) population is defined as the set of subjects who are randomized and 
have received at least one dose of PRO 140 or placebo. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035207] -baseline assessment will be 
included in the ITT population and analyzed as non-responders in the primary efficacy analysis. 
[IP_ADDRESS] Per Protocol Population  
The Per Protocol (PP) population is defined as the set of subjects who meet the ITT population 
requirements, and were not associated wi th a major protocol violation. This population will be 
identified before the database lock. The PP population will be the primary analysis population for the analysis of primary and secondary endpoints. 
[IP_ADDRESS] Safety  Population  
The Safety population is defined as  all subjects who received at least one dose of PRO [ADDRESS_1035208] data listings. Statistical analyses will be 
performed using SAS
® for Windows, version 9.3 or later. 
A SAP will be developed and approved before the database is locked. The SAP will present the detailed statistical methodology  to be used in analyzing the efficacy  and safety  data from this trial 
including details of appropriate statistical tests to examine underlying assumptions.  
8.6.3 Prognostic Factors/Covariates  
There  are no pre- planned covariates  analyses of the data from this study.  
 
8.6.[ADDRESS_1035209] listing.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  90 of 115  
 8.7.2 Demographic and Baseline Characteristics 
Demographics and baseline characteristics (i.e.,  Age, Gender, Time since HIV diagnosis, Viral 
load at Screening Visit, etc.) will be summarized using appropriate descriptive statistics.  
Medical  history of the subjects will also be provided as a by- subject  listing.  
 
8.7.3 Prior  and Concomitant Medications 
Prior and concomitant medications will be summarized for the Safety population. All prior and 
concomitant medications recorded in the eCRFs will be coded to generic term and all matching 
Anatomic Therapeutic Classification (ATC) codes using WHO Drug Summaries will be prepared 
using the coded terms. All prior and concomitant medications recorded in the eCRFs will also be listed.  
8.7.4 Efficacy  Analysis  
[IP_ADDRESS] Primary  Analysis  
The primary  analysis will be conducted on the ITT population. 
The primary efficacy endpoint for this study is proportion of participants with a ≥ 0.5 log
10 or 
greater reduction in HIV -1 RNA viral load from baseline at the end of the 1 -week double -blind 
treatment period.  
Logit model will be used to compare the primary endpoint between the treatment groups. The details will be presented in the Statistical Analysis Plan (SAP).  
The secondary efficacy  endpoints are:  
• Proportion of participants with ≥ 0.5 log
10 reduction in HIV -1 RNA viral load from 
baseline at the end of the 1 -week double- blind treatment period, stratified to each group: 
a. resistance to ART  drugs within  three  drug classes 
b. resistance to ART  drugs within  two drug classes with limited  treatment option.  
• Proportion of participants with ≥ 1 log 10 reduction in HIV -1 RNA viral load from baseline 
at the end of the 1 -week double -blind treatment period for all patients and within each 
stratum 
• Mean change from Baseline in HIV -1 RNA levels (log 10 copi[INVESTIGATOR_014]/mL) at the  end of the 1- 
week double- blind treatment period for all patients and within each stratum 
• Percentage of participants achieving HIV -1 RNA < 400 copi[INVESTIGATOR_014]/mL at week 25 for all 
patients  and within  each stratum.  (The  lower  95% confidence interval will be  at least 85%)  
• Percentage of participants achieving HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at week 25 for all 
patients  and within  each stratum.  (The  lower  95% confidence interval will be at least 80%)  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  91 of 115  
 • Mean  change from  Baseline  in HIV-1 RNA levels (log 10 copi[INVESTIGATOR_014]/mL)  at week  25 for all 
patients and within each stratum  
• Mean  change from Baseline in CD4  cell count at the end of the 1- week  double-blind 
treatment period for all patients and within each stratum  
• Mean change from Baseline in CD4 cell count at week 2 5 for all patients and within each 
stratum 
All data from the secondary  endpoints will be summarized  and tabulated  according to the variable 
type:  
• Continuous data summaries  will include:  
o Number of observations, mean, standard deviation, median, and minimum and 
maximum values.  
o Analysis of Covariance (ANCOVA) will be used for between group comparisons, if 
Normality  assumption is not met non- parametric methods (e.g., Wilcoxon test) will be 
considered.  
o Paired  t-test will be used for within  group comparisons; if Normality  assumption  is not 
met Wilcoxon signed rank sum test will be used. 
• Categorical  data summaries  will include:  
o Frequency counts and percentages.  
o Logit model will be used for inferential statistics.  
[IP_ADDRESS] Supportive  Analysis  
To assess the consistency of the Primary Analysis results, supportive analysis will be conducted 
using the PP population. Statistical methodology for the supportive analyses will be the same as that of the primary analysis, with the exception of the analys is population used. 
8.7.[ADDRESS_1035210] Deviation (SD), 
minimum and maximum values. For categorical variables data will be summarized using frequency and percentage. No inferential statistics are planned.  
[IP_ADDRESS] Adverse Events  
Adverse events wi ll be coded using Medical Dictionary for Regulatory Activities (MedDRA). 
TEAEs are defined as events with an onset on or after the first treatment. TEAEs will be summarized by [CONTACT_1570], System Organ Class, and preferred term. The following TEAE summ aries will be provided:  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  92 of 115  
 • TEAEs  by [CONTACT_168767]  
• TEAEs  by [CONTACT_756450].  
In addition, separate summaries of SAEs, and AEs resulting in discontinuation of study treatment 
will be presented.  
[IP_ADDRESS] Tolerability  Assessment  
All data from tolerability assessments of repeated subcutaneous administration of PRO 140 as assessed by [CONTACT_756451] (using Visual Analogue Scale) and by [CONTACT_1697] -evaluation of 
injection site reactions will be summarized.  
[IP_ADDRESS] Clinical Laboratory Data  
All laboratory  values will be listed. Laboratory  measurements will also be summarized.  
 
[IP_ADDRESS] Physical  Examination  
All physical examination  findings will be listed  and any abnormality will be summarized.  
 
[IP_ADDRESS] Vital Signs  
All vital sign assessment findings will be listed  and summarized.  
 
[IP_ADDRESS] ECG  Examination  
All ECG examination  findings will be listed  and any abnormality will be summarized.  
 
[IP_ADDRESS] Neurological Assessment  
All neurological assessment  findings will be listed and  any abnormality  will be summarized.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  93 of 115  
 9 ADVERSE EVENTS  (DEFINITIONS  AND REPORTING)  
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE, as provided in this protocol. During the study when there is a safety  evaluation, the Investigator or site staff will be resp onsible for detecting, documenting, and 
reporting AEs and SAEs as detailed in this section of the protocol. 
 
9.1 ADVERSE  EVENT  
An adverse event (AE)  is defined as any  unfavorable or unintended sign, symptom, or disease that 
occurs or is reported by [CONTACT_756452], or a worsening of a pre -existing condition. 
An AE may or may not be related to the study treatment.  
AEs will be elicited through direct questioning and subject reports. Any abnormalities in visit evaluations, physical examination findings or laboratory results that the Investigator believes are clinically significant to the research subject and that occurred after initiation of the first study treatment will be reported as AEs. Abnormal findings that are NOT clinically significant (NCS) should not be recorded as an AE. 
9.1.[ADDRESS_1035211] treatment visit and 
continue up until the final study visit (i.e. up to NTF -FU2 for subject who do not experience 
virolog ic failure or until viral suppression is achieved for subjects who experience virologic 
failure). All events will be followed to resolution or until [ADDRESS_1035212]’s medical records and on the eCRFs. AEs will be  
reported using customary medical terminology along with the following information: the onset and end dates, whether the  event is considered to be  a SAE (see  Section 9.2), the  impact the  event 
had on study treatment (see Section 9.1.2 ), the DAIDS AE grade (intensity) of the event (see 
Section 9.1.3), the causality of the event (see Section 9.1.4 ), whether treatment was given as a 
result of the event (see Section 9.1.5 ), and the outcome of the event (see Section 9.1.6 ). 
9.1.[ADDRESS_1035213] the event had on the study treatment will be assessed as either: none, study treatment interrupted, study treatment discontinued, or not applicable. The “not applicable” assessment will 
be used only when the subject is no longer in the treatment phase of the protocol, or if the outcome of the event was “death”.  
9.1.3 DAIDS  AE Grade  (Severity)  Assessment  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  95 of 115  
 known response pattern  to treatment with the study  treatment.  
3. Possibly re lated : This category applies to those AEs which, after careful medical 
consideration at the time they are evaluated, are judged unlikely but cannot be ruled out 
with certainty to the study treatment. An AE may be considered possible if or when (must have t wo): (1) it follows a reasonable temporal sequence from administration of the study 
treatment. (2) It could not readily have been produced by [CONTACT_1130]’s clinical state, environmental or toxic factors, or other therapi[INVESTIGATOR_26455]. (3) Disappears or is decreased upon discontinuation of the study treatment. (4) It follows a 
known response pattern to treatment with the study treatment. 
4. Remotely related : In general this category can be considered applicable to those AEs 
which, after careful med ical consideration at the time they  are evaluated, are judged likely 
to be unrelated  to the study treatment.  An AE may  be considered  unlikely if or when  (must 
have two): (1) it does not follow a reasonable temporal sequence from administration of the study treatment. (2) It could not readily  have been produced by [CONTACT_1130]’s clinical state, 
environmental or toxic factors, or other therapi[INVESTIGATOR_26455]. (3) 
Disappears or is decreased upon discontinuation of the study treatment. (4) It does not 
follow a known response pattern to treatment with the study treatment. 
5. Unrelated : This category applies to those AEs which, after careful consideration at the 
time they are evaluated, are  clearly  and incontrovertibly due to extraneous causes (disease, 
environment, etc.) and determined with certainty to have no relationship to the stud y 
treatment.  
9.1.[ADDRESS_1035214] in terms of treatment provided will be as either: none, medication administered, non-medication therapy administered, surgery, or other (with a specification).  
9.1.6 Outcome  Assessment  
The outcome of the event will be assessed as either: resolved, resolved with sequelae, ongoing, or death. Only one AE per subject is allowed to have an outcome assessment as “death.” If there are 
multiple  causes of death for  a given subject,  only the primary  cause of death  will have an outcome 
of death. 
9.1.7 Expected  / Anticipated  Adverse Events  
The most common potential study  drug- related adverse reaction reported is mild headache. Other 
adverse events likely to be related to the drug include mild to moder ate diarrhea, nausea, and 
fatigue.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035215] the ability to safely and successfully deliver the drug. Local inje ction -site 
reactions may  include pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis, 
etc. For SC injections, bleeding, absorption of the drug, leakage of drug, and induration at the 
local injection site can be additional complicatio ns. Other AEs that are common to monoclonal 
antibody- based therapi[INVESTIGATOR_616497], headache, backache, malaise, fever, pruritus, rash, nausea, 
tingling, and hypertension. 
SC injection -related  events will be monitored  according to the guidelines provided in  Section  17.2 
(Division  of AIDS Table for  Grading  the Severity  of Adult and Pediatric  Adverse Events [DAIDS 
AE Grading Table]).  Injection -site reactions thought to be directly related to the injection are 
considered to be AEs of special interest, and a separate guideline for the acquisition of data  
related to this AE of special interest is provided in Section 17.[ADDRESS_1035216] should be reevaluated closely until the AE returns to Grade ≤2, at which time study treatment may be 
reintroduced at the  discr etion of  the site investigator. If the  same Grade  [ADDRESS_1035217] be permanently discontinued. Subjects experiencing Grade 3 AEs requiring permanent discontinuation of study treatment should be 
followed closely for resolution of the AE to Grade ≤ [ADDRESS_1035218] be notified.  
Subjects with Grade  3 asymptomatic  laboratory  abnormalities in cholesterol, creatine  kinase (CK) 
or triglycerides may continue study treatment. 
For grade 4 events permanently  discontinue therapy.  
 
9.2 SERIOUS  ADVERSE  EVENTS  (SAE)  
A SAE  is defined as any AE that: 
• Results in death  
 
• Is life threatening (the subject  is at immediate  risk of dying from  the AE) 
 
• Requires subject  hospi[INVESTIGATOR_756434]  
 
• Results in persistent  or significant disability/incapacity  
 
• Is a congenital anomaly/birth  defect  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035219] be  
documented and reported CytoDyn, Inc. Participants who become pregnant will be entered into the Antiretroviral Pregnancy Registry ( http://www.apregistry.com).  
 
9.3 REPORTING  OF SERIOUS  ADVERSE  EVENTS  
The Investigator is required to report all SAEs that occur during the time period specified i n 
Section 9.1.1. Once the Investigator becomes aware of an SAE, he/she must report the SAE to 
Safety Department within 24 hours: 
 
The Medical Monitor may request additional supporting documentation as it becomes 
available, such as lab reports, ECG reports, discharge summary, hospi[INVESTIGATOR_11533], etc. 
The Investigator is also responsible for reporting all SAEs to the appropriate Institutional Review 
Board (IRB) in accordance with local laws and regulations. The Investigator is responsible for maintaining documentation in the study file that indicates the IRB has been properly notified. Under 21 CFR 312.32(c), the sponsor is required to notify FDA and all participating investigators 
in an IND safety report (i.e., 7 - or 15- day expedited report) of potentially serious risks from 
clinical trials or any other source as soon as possible, but no later than 15 calendar days after the sponsor receives the safety information and determines that the information qualifies for  
reporting. Participating investigators include all investigators to whom the sponsor is providing drug under any of its INDs or under any investigator’s IND (21 CFR 312.32(c)(1)). 

Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035220] be closely followed 
until sufficient information is obtained to indicate a return to normal status or until the event stabilizes at a level acceptable to the investigator (i.e., re covery, return to baseline status, no 
further improvement expected, or death).  
For each SAE indicated as an unresolved event on the initial report, regardless of whether the subject completed the study or withdrew, the site should submit a follow -up report  with updated 
information.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035221] ACCESS  TO SOURCE  DATA/DOCUMENTATION 
Subjects will be identified on eCRFs by a unique subject identification number and on source 
documents by [CONTACT_11572]. No personal identifier will be used in any publication or communication used to support this research study. The subject ident ification number will be  
used if it becomes necessary to identify data specific to a single subject.  
The monitors, auditors, personnel authorized by [CONTACT_1034], the local IRB, and the FDA are eligible to review medical and research records related to this study as a part of their  
responsibility to protect human subjects in clinical research and will be given direct access to source data and documentation (e.g., medical charts/records, printouts etc.) for source data verification, provided that subject conf identiality is maintained in accordance with local 
requirements. Access to electronic medical records may be governed by [CONTACT_714239].  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  100 of 115  
  
11 QUALITY CONTROL  AND QUALITY ASSURANCE 
 
11.1 MONITORING  REQUIREMENTS  
In an effort to fulfill the obligations outlined in 21 Code of Federal Regulations (CFR) Part 312 
and ICH guidelines which requires the Sponsor to maintain current personal knowl edge of the 
progress of a study, the Sponsor's designated monitor will visit the center(s) during the study as well as maintain frequent telephone and written communication. The Investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary and provide access to medical 
records to ensure that data are being  recorded  adequately, that data are verifiable  and that protocol 
adherence is satisfactory.  
The Investigator will permit representatives of the Sponsor and/or designated CRO to inspect all eCRFs and corresponding study subject original medical records (source documents) at regular intervals throughout the study. Subject original medical records and other relevant data must be available to support all data recorded in the eCR F. In addition to the original medical records, 
these data may include but are not limited to, study, laboratory and diagnostic reports, neurological examination results, etc.  
Site inspections serve to verify strict adherence to the protocol and the accuracy of the data being entered on the case report forms, in accordance with federal regulations. A Monitoring Log will  
be maintained at each study site which the monitor will sign, date and state the type of visit.  
The Investigator should be aware that the study site and subject records may be inspected by [CONTACT_424166], FDA or other regional regulatory authority.  
For the IA, a cut -off date for data collection and monitoring  will be determined and sites will be 
requested to provide current information up to the cut- off date.  
11.2 A
CCEPTABILITY  OF CASE  REPORT FORMS  (CRF S) 
Electronic CRFs must be completed for each subject who has signed an informed consent form. 
For subjects who are screen failures, this would be limited to the screen failure eCRF page. All 
source documents and eCRFs will be completed as soon as possible af ter the subject's visit. 
Corrections to data on the eCRFs will be documented. The Investigator will review eCRFs to indicate that, to his/her knowledge, they are complete and accurate. Electronic CRFs will be reviewed by [CONTACT_1034]’s or designated CRO’s monitor, who will make a decision as to their acceptability.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035222] obtaining the concurrence of 
the Sponsor. Approval by [CONTACT_737]’s IRB must  also be obtained prior  to implementation  of 
the change, with two exceptions: 
1. When  necessary  to eliminate  apparent  immediate  hazard  to the subject;  or 
2. When  the modification  does not involve the subject’s participation  in the trial. 
An amendment may also require  modification  of the informed  consent form.  The Investigator  will 
provide an approval letter for the amendment and revised informed consent form, if applicable, to 
the Sponsor. An amendment must be in writing and it must be dated by [CONTACT_616535]. If necessary, the Sponsor will submit protocol amendments to FDA and other appropriate regulatory authorities and notify other Investigators using this protocol.  
 
11.[ADDRESS_1035223] be documented in the eCRFs.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  102 of 115  
 12 DATA MONITORING  COMMITTEE (DMC)  
The study will be monitored by [CONTACT_3153] (DMC) to ensure patient safety and to 
assess efficacy. The CRO is responsible for the overall management of DMC, including developmen t of its charter and membership selection. The DMC will be managed in 
conformance with the FDA guidelines for DMC independence, management, and oversight. 
The DMC will monitor the  safety  of the trial from the  beginning and at approximately six month 
interv als thereafter  based on enrollment. The DMC will also assess the study for futility  once all 
the randomized subjects complete the [ADDRESS_1035224] three independent members (including clinicians with expertise in HIV disease, a neurologist or psychiatrist and at least one biostatistician) and will review all safety signals including number of virologic non -response 
and virologic rebounds, unexpected AEs, all related AEs, all SAEs, and all deaths during the Treatment and Follow- Up Phases.  
All expedited safety reports will be provided in real time to the DMC chair upon being reported to FDA. At each meeting, the DMC will be authorized to unblind the study upon unani mous 
vote in the event of any concerns about safety or lack of efficacy. Unblinded CRO personnel, separate and independent of the blinded CRO personnel, will supply the DMC with all  
necessary tables and listings to perform their independent review. 
The Sponsor will be invited  to attend  open sessions where  data remain  blinded, but will not attend 
closed sessions where data are discussed in more detail with potential unblinding. The DMC will 
make the following recommendations at each safety evaluation:  
 Continue the study as planned;  
 Modify the study and continue;  
 Terminate  the study;  
 Gather  more data to address a specific safety  issue and reconvene;  
 Other  (e.g., request changes  to the protocol and propose sanctions).  
The Sponsor retains  the responsibility  to contact  [CONTACT_756453].  
A further description  of the DMC reporting requirements,  meeting  frequency, and the study 
stoppi[INVESTIGATOR_007]/continuation criteria can be found in the DMC charter. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  103 of 115  
 13 ETHICS  AND REGULATORY REQUIREMENTS  
This study is to be conducted in accordance with the specifications of this protocol and in 
accordance with principles consistent with De claration of Helsinki, GCP, 21 CFR Part 312, ICH 
E6, HIPAA regulations in 45 CFR Part 164 (US only), and the Belmont Principles of respect for persons, beneficence, and justice. No protocol changes will be implemented without the prior review and approval of the IRB, except when the modification does not involve the subject’s 
participation in the trial or where it may be necessary to eliminate an immediate hazard to a research subject. In the latter case, the change will be reported to the IRB as soon as po ssible, 
according to IRB regulations. 
Additionally, all study products used in this study are manufactured, handled and stored in 
accordance with applicable GMP and the products provided for this study will be used only in accordance with this protocol.  
 
13.[ADDRESS_1035225] /INDEPENDENT  ETHICS  COMMITTEE  (IRB/IEC)  
The Principal Investigator [INVESTIGATOR_616498]/Independent 
Ethics Committee (IRB/IEC) with all appropriate materials as required by [CONTACT_11577]/IEC, including but not limited to the clinical study protocol, informed consent form, and a ny 
advertising materials. The study will not be initiated until the IRB/IEC provides written approval of the aforementioned documents and until approval documents have been obtained by [CONTACT_079] [INVESTIGATOR_26457]. The Investi gator will not participate in 
the decision. If the Investigator is an IRB or IEC member, documentation must be provided indicating recusal from the approval process. Appropriate reports on the progress of this study by [CONTACT_079] [INVESTIGATOR_756435]/IEC as required by [CONTACT_424169]. The  
Investigator is required to maintain an accurate  and complete record of all written  correspondence 
to and received fro m the IRB/IEC, and must agree to share all such documents and reports with 
the Sponsor. 
No changes from the final approved protocol will be initiated without the IRB/IEC’s prior written 
approval or favorable opi[INVESTIGATOR_1101] a written amendment, except when nece ssary to eliminate 
immediate hazards to the subjects or when the modification does not involve the subject’s participation in the trial.  
 
13.2 INVESTIGATOR ’S RESPONSIBILITIES  
The Investigators are responsible for performing the study in full accordance with the  protocol 
and the current revision of the Declaration of Helsinki, the Good Clinical Practice: Consolidated Guideline, approved by [CONTACT_11580],  and any applicable national and local  laws and regulations.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035226] will be 
given to all subjects by [CONTACT_11219]/or designee. Written informed consent will be 
obtained from each subject before any procedures or assessments that would not otherwise be required for the care of the subject are done and after the aims, methods, anticipated benefits, potential hazards, and insurance arrangements in force are explained and the subject has been given sufficient time to ask questions and consider participation in the study. It will also be explained  to the subjects that  they are free to refuse  entry  into the study and free  to withdraw from 
the study at any time without prejudice to future treatment. It is permissible for a third person (e.g., a family member) to be present during the explanation of the study. 
The written Informed Consent Form ICF is to be in compliance with CFR 21 Part 50.27 and GCP guidelines. The Sponsor and/or designated CRO will approve the ICF and all amendments to the ICF prior to submission to the IRB/IEC. A copy of the ICF to be used will be submitted by [CONTACT_26492]/IEC for review and approval prior to the start of the study. Each study site 
must provide the Sponsor with an unsigned copy of IRB/IEC -approved ICF along with applicable 
documentation to support this approval. The original signed ICF is retained in the subject's study records, and a cop y is provided to the subject. A second copy may be filed in the subject’s  
medical record, if allowed by [CONTACT_10569].  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035227]'s medical record. If separate 
research records are maintained by [CONTACT_737](s), the medical record and the research  
records will be considered the source documents for the purposes of auditing the study. 
Applicable source data will be m anually transcribed to the approved eCRFs. The Investigator is 
ultimately  responsible for the accuracy  of the data transcribed on the  forms. All source  documents 
and eCRFs will be completed as soon as possible after the subject's visit.  
The Investigator will review eCRFs to indicate that, to his/her knowledge, they are complete and 
accurate. Designated source documents will be signed and dated by [CONTACT_26493]. The Investigator must agree to complete and maintain source documents and eCRFs  
for each subject participating in the study.  
All research data will be entered, either electronically or manually, into a computerized database. The clinical database will be designed by [CONTACT_424170] [ADDRESS_1035228]’s study number, name, date of birth, and unique hospi[INVESTIGATOR_11538]. This list will be kept by [CONTACT_26494]. A notation will be made in the subject’s case history/medical chart that he/she is participating in a clinical study  and 
has provided a signed and dated ICF as well as a release for protected health information as required by [CONTACT_11582]. The Investigator must also maintain a separate screening log of all the subjects screened for participation in the study; it should include gender, age, eligibility status, reason for ineligibility, if applicable; and study allocated subject numbe r, if applicable. 
 
14.2 CLINICAL DATA  MANAGEMENT  
The Sponsor and/or designated CRO will be responsible for the processing and quality control 
(QC) of the data. Data management will be carried out as described in the Sponsor’s or CRO’s 
standard operating procedures (SOPs) for clinical studies.  
The handling of data, including data QC, will comply with regulatory guidelines (e.g., ICH E6 GCP, and local regulations where applicable) and the Sponsor’s or the CRO’s SOPs as well as provisions of the study- specific Data Management Plan.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  106 of 115  
 14.3 ARCHIVING  
All study documentation at the Investigator site and Sponsor site will be archived in accordance 
with ICH GCP E6 and the Sponsor’s quality standards and SOPs. 
The Investigator will maintain all research records, re ports, and case history reports for a period 
of two years after  regulatory approval of  the investigational product. If  no application is filed or  if 
the application is not approved, records must be maintained for two years after all investigations 
have been completed, terminated or discontinued and the FDA has been notified. 
These documents should be retained for a longer period however, if required by [CONTACT_756454] (as per 
GCP 5.5.11). 
At the completion of the study, details of the archival process must be provided to the Sponsor. 
Study records are subject to inspection by [CONTACT_11583]. 
Records to be retained  by [CONTACT_11584], but are not restricted  to: 
• Source data and the primary records upon which they are based (e.g., subject’s progress 
notes, adverse event data, test results, and any other diagnostic procedures required to evaluate the progress of the study) 
• Completed  CRFs  
• Signed protocols and protocol amendments  
• Laboratory  results,  ranges, and certifications  
• Product (e.g., IP supplies) and accountability  records  
• Study personnel signature  [CONTACT_26500] 
• Monitoring logs 
• Correspondence to and from  the Sponsor, designee and IRB 
• Investigator and sub- investigator  CVs 
• Signed informed  consent  and protected  health  information  consent  forms  
• Subject screening  and enrollment log 
• SAE  reports  
• IRB approval and re-approval letters  
• Other  documents pertaining to the conduct of the study  
These documents must be maintained and kept on file by [CONTACT_424173]. 
At the completion of the study, details of the archival process must be provided to the Sponsor. 
Study records s hould not be transferred from site or destroyed without prior written agreement 
between the Sponsor and the study Investigator. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  107 of 115  
 15 PUBLICATION  PLAN 
All information supplied by [CONTACT_756455], is considered confidential information. This information  includes, but is not 
limited  to, the Investigator’s Brochure (IB), clinical protocol, case report forms  and other 
scientific data. Any  data collected during the study are also considered confidential. This 
confidential information  shall remain the sole property of CytoDyn, shall not be disclosed to 
others without the written  consent of  CytoDyn, and shall not be  used except in the  performance 
of this study. 
It is understood by [CONTACT_756456] 140. Therefore, this information may be disclosed a s required to other Investigators or appropriate regulatory authorities. By [CONTACT_520871], the Investigator understands that he/she has an obligation to provide the Sponsor with complete test results and all data developed during this trial.  
Publication  and Disclosure: Because this is a multi- center  trial, the site and Investigator shall  not 
independently publish, publicly disclose, present or discuss any results of or information pertaining  to the site’s and Investigator’s activities conducted under this protocol until  such multi- 
center publication is released with the written approval and under the direction of Sponsor. Notwithstanding the foregoing, if a multi -center publication is not released within eighteen (18) 
months after completion of analysis of all study data from all studies conducted within the multi - 
center trial, both the site and Investigator shall have the right to publish the results of and information pertaining to the site’s and Investigator’s activities conducted under this protocol and the clinical trial agreement, subject to the prior review and written approval of Sponsor. The site 
and Investigator agree to submit any proposed manuscript, presentation or other public disclosure 
regarding the  study to Sponsor for review at least thirty (30) days prior to submitting such 
proposed manuscript to a publisher or delivering or making such presentation or other public 
disclosure to any third party. Within thirty (30) days of its receipt, Sponsor shal l advise the site 
and/or Investigator, as the case may be, in writing of any information contained therein that is confidential information (other than research results included in a proposed manuscript) or that may impair Sponsor’s ability to obtain paten t protection. Sponsor shall have the right to require 
the site and/or Investigator, as applicable, to remove specifically identified confidential information (but may not require removal of research results from a proposed manuscript) and/or to delay the proposed submission or delivery of the proposed manuscript or presentation, or other public disclosure, for an additional sixty (60) days to enable Sponsor to seek patent protection. The site and Investigator shall not publish, publicly disclose, present or  discuss any results of or 
information pertaining to the site’s and Investigator’s activities prior to completion of the trial, even  if the multi- center  trial or the study is terminated  before its completion  and the final clinical  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035229] to any endpoints or analyses other than those specified 
in this protocol.  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  109 of 115  
 16 REFERENCES  
Demeter LM Shafer RW, Meehan PM, Holden -Wiltse J, Fischl MA, Freimuth WW, Para 
MF, Reichman  RC. Delavirdine susceptibilities  and associated  reverse transcriptase mutations  in 
human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine 
monotherapy (ACTG 260). Antimicrob.Agents Chemother.. - 2000. - Vol. 44. - pp. 794-797. 
Gulick  RM Lalezari  J, Goodrich J, Clumeck  N, DeJesus E, Horban A, Nadler  J, Clotet  B, 
Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for Previously Treated Patients with R5 HIV- 1 Infection  NEJM. - October 2, 2008. - Vol. 359 : 14. - pp. 1429-1441. 
Jacobson JM Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio  P, Stambler  N, Rotshteyn Y, Marozsan  AJ, Maddon PJ, Morris SA, Olson  WC. 
study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV- infected 
adults. Antimicrob  Agents Chemother.. - 2010. - Vol. 54. - pp. 4137-42.. 
Jacobson JM Saag MS, Thompson  MA,  Fischl  MA,  Liporace R, Reichman  RC, Redfield 
RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, 
Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Ols Antiviral activity  of single-dose PRO 140, a CCR5  monoclonal antibody, in 
HIV- infected adults.  J Infect Dis.. - 2008. - Vol. 198. - pp. 1345-52.. 
Jacobson JM Thompson MA,  Lalezari  JP, Saag MS, Zingman BS, D'Ambrosio  P, Stambler 
N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Anti -HIV- [ADDRESS_1035230] Dis.. - 2010. - Vol. 201. - pp. 1481-7. 
Marozsan  A. J., T. Parsons,  W. Huang,  E. Stawiski,  J. M. Whitcomb,  P. J. Maddon,  and W. 
C. Olson.  Clonal analysis of HIV-1 co-receptor tropi[INVESTIGATOR_756436] 
140, a CCR5 monoclonal antibody. 48th Annual ICAAC / IDSA 46th Annual Meeting. - 
Washington, DC. : [s.n.], 2008. - Vols. Abstract H -1218. 
Moyle G Gatell J, Perno CF, Ratanasuwan w, Schechter M, Tsoukas C Potential for new antiretrovirals  to address  unmet needs in the management  of HIV-[ADDRESS_1035231] TAK-220 on human CCR5. 
Antimicrob  Agents Chemother. - 2005. - Vol. 49(11). - pp. 4708- 4715..  
Office of AIDS Research Advisory Council AIDSinfo Guidelines for the Use of Antiretroviral 
Agents in HIV-1- Infected  Adults and Adolescents [Online] AIDS Info.  - Nov 13, 2014. - Dec 29, 
2014. - http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 
Richman D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. 
Cheeseman, K. Barringer, D. Pauletti. Nevirapi[INVESTIGATOR_756437] 1 selected  during therapy. J Virol.. - 1994. - Vol. 68. - pp. 1660- 
1666..  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-[ADDRESS_1035232] J, 
Giacobini E, Hirschel B, Du Pasquier RA Cognitive dysfunction in HIV patients despi[INVESTIGATOR_147171] - 
standing suppression of viremia.. - 2010. - Vol. 24. - pp. 1243-1250. 
Tang  MW  Shafer  RW HIV-1 Antiretroviral Resistance:  Scientific  Principles  and Clinical 
Applications Drugs. - 2012. - pp. e1-e25. 
Thomps on M., Lalezari, J., Saag, M., Jacobson, J., Zingman,  B., Stambler,  N., D'Ambrosio, 
P., Maddon, P., Olson, W., and Morris, S. Weekly and bi-weekly subcutaneous PRO 140 
demonstrates potent, sustained antiviral activity.  16th Conference on Retroviruses and 
Opportunistic Infections. - Montreal QE, Canada, : [s.n.], 2009. - Vol. Abstract #571a. 
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  111 of 115  
 17 APPENDIX  
 
17.1 APPENDIX  I: AIDS-D EFINING  CONDITIONS  
• Bacterial  infections,  multiple  or recurrent*  
• Candidiasis  of bronchi,  trachea,  or lungs 
• Candidiasis  of esophagus† 
• Cervical cancer,  invasive§ 
• Coccidioidomycosis,  disseminated or extrapulmonary 
• Cryptococcosis,  extrapulmonary 
• Cryptosporidiosis,  chronic intestinal (>1 month's duration) 
• Cytomegalovirus disease  (other  than liver,  spleen,  or nodes),  onset at age >1 
month 
• Cytomegalovirus retinitis (with loss of vision)† 
• Encephalopathy,  HIV related  
• Herpes simplex: chronic  ulcers  (>1 month's duration)  or bronchitis, 
pneumonitis, or esophagitis (onset at age >1 month)  
• Histoplasmosis,  disseminated or extrapulmonary 
• Isosporiasis,  chronic  intestinal (>1 month's duration) 
• Kaposi  sarcoma† 
• Lymphoid  interstitial pneumonia  or pulmonary  lymphoid hyperplasia  complex*† 
• Lymphoma,  Burkitt (or equivalent term)  
• Lymphoma,  immunoblastic  (or equivalent term)  
• Lymphoma,  primary, of brain  
• Mycobacterium avium complex  or Mycobacterium  kansasii,  disseminated or 
extrapulmonary† 
• Mycobacterium tuberculosis of any site, pulmonary,†§ disseminated,† or 
extrapulmonary† 
• Mycobacterium, other  species or unidentified species,  disseminated† or 
extrapulmonary† 
• Pneumocystis jirovecii pneumonia† 
• Pneumonia,  recurrent†§ 
• Progressive  multifocal leukoencephalopathy 
• Salmonella  septicemia,  recurrent  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  112 of 115  
 • Toxoplasmosis of brain,  onset at age >1 month† 
• Wasting syndrome  attributed to HIV 
 
* Only  among  children  aged  <13 years.  (CDC.  1994  Revised  classification  system for human immunodeficiency 
virus infection in children less than 13 years of age. MMWR 1994;43[No. RR -12].) 
† Condition  that might be diagnosed  presumptively.  
§ Only  among adults and adolescents aged >13 years. (CDC. 1993 Revised classification system for HIV infection 
and expanded  surveillance  case definition  for AIDS  among  adolescents  and adults.  MMWR  1992;41[No.  RR-17].)  
 
 
Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  113 of 115  
 17.2 APPENDIX  II: DIVISION  OF AIDS  TABLE FOR  GRADING  THE  SEVERITY OF ADULT  AND 
PEDIATRIC ADVERSE  EVENTS  (DAIDS  AE GRADING  TABLE ) 
http://rsc.tech - 
res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_NOV2014.pdf  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  114 of 115  
  
17.3 APPENDIX  III: ADVERSE  EVENTS  OF SPECIAL  INTEREST : INJECTION  SITE REACTIONS  
The following table should be used to characterize injection -site reactions and provide appropriate 
grading of severity (DAIDS and modified additions). 
 
 
Injection -site Reactions  
 
Parameter  Grade  1 (Mild)  Grade 2 
(Moderate)  Grade  3 (Severe)  Grade 4 
(Potentially  life- 
threatening)  
Injection -site pain Pain without  Pain without  Pain without  Pain without  
 touching  or pain touching  or pain touching  or pain touching  or pain 
 when  area is when  area is when  area is when  area is 
 touched:  no or touched  limiting  touched  causing  touched  causing  
 minimal  limitation  use of limb OR inability  to perform  inability  to perform  
 of use of limb causing  greater  usual  social  and basic  self-care 
  than minimal  functional  function  OR 
  interference  with activities  hospi[INVESTIGATOR_756438]  (other  than 
  functional   emergency  room  
  activities   visit)  indicated  for 
    management  of 
    pain/tenderness  
Characterization  of Erythema  OR Erythema  OR Ulceration  OR Necrosis  
the injection  site, if induration  of 5x5 induration  OR secondary  infection  (involving  dermis  
not normal  cm - 9x9 cm  (or 25 Edema  >9 cm any OR Phlebitis  or and deeper  tissue)  
 cm2-81 cm2)  diameter  (or >81 Sterile  abscess  OR  
  cm2)  drainage   
Pruritus  associated  Itching  localized  to Itching  beyond  the Generalized  itching  N/A 
with injection  injection  site AND  injection  site but causing  inability  to  
 relieved  not generalized  OR perform  usual   
 spontaneously  or itching  localized  to social  and  
 <48 hours  of injection  site functional   
 treatment  requiring  ≥48 activities   
  hours  treatment    
Bleeding  Initial  bleed  that Bleeding  that Continued  bleeding  N/A 
 does not exceed  exceeds  bandage  that requires   
 bandage  and and spontaneously  change  of dressing   
 spontaneously  stops  and alternative   
 stops   injection  site  
Absorption  of drug Minor  elevation  of Leakage  at Leakage  at  
 skin at injection  injection  site injection  site that  
 site but no leakage  ceases  with does not cease  with  
 of injection  decrease  in decrease  in  
 material  injection  rate injection  rate  
Protocol  # PRO  140_CD  02 
Version  9.0 
Date:  08-Jan-2018  
CONFIDENTIAL  Page  115 of 115  
 17.4 APPENDIX  V: NEUROLOGICAL  ASSESSMENT  
 
Three Question  Screening  Survey  (Simioni,  et al, 2010)  
1. ‘Do you experience frequent memory  loss (e.g. do you forget the occurrence of special 
events even the more recent ones, appointments, etc.)’?  
2. ‘Do you feel that you are slower  when  reasoning, planning activities,  or solving problems’?  
3. ‘Do you have difficulties  paying attention  (e.g. to a conversation, a book, or a movie)’?  
 
 
For each question, subjects should provide one of the following  answers:  ‘never’, ‘hardly ever’,  or 
‘yes, definitely’. 
If subject answers “yes,  definitely”  to any question, Investigator may use additional neurological 
assessment modalities at its discretion.  